<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GAMMAGARD- human immunoglobulin g injection, solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use GAMMAGARD LIQUID safely and effectively.  See full prescribing information for GAMMAGARD LIQUID.<br>GAMMAGARD LIQUID, Immune Globulin Infusion (Human), 10% Solution, for intravenous and subcutaneous administration<br><br>Initial U.S. Approval: 2005</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:  <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">THROMBOSIS</span>, RENAL DYSFUNCTION and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">ACUTE RENAL FAILURE</span></span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors.</span></dd>
<dt>•</dt>
<dd><span class="Bold">Renal dysfunction, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur in predisposed patients with immune globulin intravenous (IGIV) products including GAMMAGARD LIQUID.  Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose.  GAMMAGARD LIQUID does not contain sucrose.</span></dd>
<dt>•</dt>
<dd><span class="Bold">For patients at risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and assess blood viscosity in patients at risk of hyperviscosity.</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><dl>
<dt>•</dt>
<dd>Boxed Warning; Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> (<a href="#ID_dc1aa7fc-a7db-4b39-8a77-0e868c0a0142">5.4</a>)                                                                  09/2013</dd>
</dl></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:  <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">THROMBOSIS</span>, RENAL DYSFUNCTION and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">ACUTE RENAL FAILURE</span></span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors.</span></dd>
<dt>•</dt>
<dd><span class="Bold">Renal dysfunction, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur in predisposed patients with immune globulin intravenous (IGIV) products including GAMMAGARD LIQUID.  Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose.  GAMMAGARD LIQUID does not contain sucrose.</span></dd>
<dt>•</dt>
<dd><span class="Bold">For patients at risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and assess blood viscosity in patients at risk of hyperviscosity.</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><dl>
<dt>•</dt>
<dd>GAMMAGARD LIQUID is an immune globulin infusion (human) indicated as replacement therapy for primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (PI) in adult and pediatric patients two years of age or older. (<a href="#ID_bd8ce6f8-5a04-48c6-817c-1bb343f93c37">1</a>)</dd>
<dt>•</dt>
<dd>GAMMAGARD LIQUID is indicated as a maintenance therapy to improve muscle strength and <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> in adult patients with <span class="product-label-link" type="condition" conceptid="4046338" conceptname="Motor neuropathy with multiple conduction block">Multifocal Motor Neuropathy</span> [MMN]. (<a href="#ID_bd8ce6f8-5a04-48c6-817c-1bb343f93c37">1</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table width="100%">
<col width="35%">
<col width="25%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="Highlighta"><span class="Bold">Dose </span> </p></td>
<td class="Botrule Lrule Toprule"><p class="Highlighta"><span class="Bold">Initial Infusion Rate</span> </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="Highlighta"><span class="Bold">Maintenance Infusion Rate</span> </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="Highlighta"><span class="Bold">Intravenous Administration</span> </p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="Highlighta"><span class="Bold">PI</span> </p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="Highlighta">300 to 600 mg/kg every 3 to 4 weeks based on clinical response </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">0.5 mL/kg/hr <br>(0.8 mgkg/min) <br>for 30 minutes  </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">Increase every 30 minutes <br>(if tolerated) up to 5 mL/kg/hr (8 mg/kg/min) </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="Highlighta"><span class="Bold">MMN</span> </p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="Highlighta">Dose range 0.5 to <br>2.4 grams/kg/month <br>based on clinical response </p></td>
<td class="Botrule Lrule" align="center">
<p class="Highlighta">0.5 mL/kg/hr </p>
<p class="Highlighta">(0.8 mg/kg/min) </p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">Infusion rate may be advanced if tolerated to 5.4 mL/kg/hr (9 mg/kg/min) </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="Highlighta"><span class="Bold">Subcutaneous Administration</span>: </p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="Highlighta"><span class="Bold">PI</span> </p></td></tr>
<tr class="Last">
<td class="Lrule">
<p class="Highlighta">Initial Dose is 1.37 × previous intravenous dose divided by # of weeks between intravenous doses.<br> </p>
<p class="Highlighta">Maintenance dose is based on clinical response and target IgG trough level (<a href="#ID_7ee66650-e105-4338-a0a3-8100155179cc">2.2</a>). </p>
</td>
<td class="Lrule">
<p class="Highlighta"><span class="Underline">40 kg BW and greater: </span> 30 mL/site at 20 mL/hr/site.<br> </p>
<p class="Highlighta"><span class="Underline">Under 40 kg BW:</span><br>20 mL/site at 15 mL/hr/site. </p>
</td>
<td class="Lrule Rrule">
<p class="Highlighta"><span class="Underline">40 kg BW and greater: </span><br>30 mL/site at 20 to 30 mL/hr/site. </p>
<p class="Highlighta"><span class="Underline">Under 40 kg BW:</span> 20 mL/site at 15 to 20 mL/hr/site. </p>
</td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>Ensure that patients with pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> are not volume depleted; discontinue GAMMAGARD LIQUID if renal function deteriorates. (2.3, 5.2)</dd>
<dt>•</dt>
<dd>For patients at risk of renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable. (2.3, 5.2, 5.4)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Aqueous solution containing 10% IgG (100 milligram/mL) (<a href="#ID_b0d5b92d-43df-4c67-80a1-83454b167dea">3</a>).  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Anaphylactic or severe systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to Immune Globulin (Human) (<a href="#ID_8088d771-b7bc-40fe-b61c-4c01305bae19">4</a>).</dd>
<dt>•</dt>
<dd>IgA deficient patients with antibodies against IgA and a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (<a href="#ID_8088d771-b7bc-40fe-b61c-4c01305bae19">4</a>).</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>IgA deficient patients with antibodies to IgA are at greater risk of developing severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>. (<a href="#ID_91d0bc6c-2dce-410a-88e1-d1892dac88f1">5.1)</a>
</dd>
<dt>•</dt>
<dd>Monitor renal function, including blood urea nitrogen, serum creatinine, and urine output in patients at risk of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. (<a href="#ID_3e0e9874-b2e7-4307-83ea-dec5918648ab">5.2)</a>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, increased serum viscosity and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur. (<a href="#ID_fcce5a1f-7b34-4b41-a502-d906e584fa82">5.3)</a>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur. Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and assess blood viscosity for those at risk for hyperviscosity. (<a href="#ID_dc1aa7fc-a7db-4b39-8a77-0e868c0a0142">5.4)</a>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome (AMS) may occur. (<a href="#ID_f7824ad1-be23-4e6b-904a-0595c71e83bb">5.5)</a>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> can develop.  Monitor for clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> and <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. (<a href="#ID_45fc3bce-c890-4fda-a97c-f5b6ff182990">5.6)</a>
</dd>
<dt>•</dt>
<dd>Monitor patients for pulmonary adverse reactions (transfusion-related acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">lung injury</span>, <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>). <a href="#ID_c3ffdc21-4ded-4610-901d-3abb1a0f07a1">(5.7)</a>
</dd>
<dt>•</dt>
<dd>Product is made from human blood may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent (<a href="#ID_e4d1e232-a733-47f6-b9a8-0e4af345a6f3">5.8) </a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Serious adverse reactions which occurred in the clinical trials were <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> (<a href="#ID_cfaf8128-6c37-466e-ad71-b01b284c3fa8">6.1</a>) </p>
<p class="Highlighta">The most common adverse reactions observed in ≥5% of patients were (<a href="#ID_cfaf8128-6c37-466e-ad71-b01b284c3fa8">6.1</a>): </p>
<p class="Highlighta"><span class="Bold">PI</span>: <span class="Underline">Intravenous Administration</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">oedema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">cardiac murmur</span>.  </p>
<p class="Highlighta"><span class="Underline">Subcutaneous Administration</span>: Infusion site (local) event, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4109301" conceptname="Increased systolic arterial pressure">blood pressure systolic increased</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, oropharygneal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>. </p>
<p class="Highlighta"><span class="Bold">MMN</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>. </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Passive transfer of antibodies may transiently interfere with the immune responses to live virus vaccines, such as <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>. (<a href="#ID_5bc60e17-40fa-4360-ae59-93b87a2c6429">7</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: No human or animal data. Use only if clearly indicated. (<a href="#ID_ac7cefcf-a776-4f95-abd8-9fc39fb52a35">8.1</a>)</dd>
<dt>•</dt>
<dd>Geriatric: In patients over age 65 or in any patient at risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, do not exceed the recommended dose, and infuse GAMMAGARD LIQUID at the minimum infusion rate practicable. (<a href="#ID_97a8d872-aec4-4b45-a9ab-7f450d48a63e">8.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">THROMBOSIS</span>, RENAL DYSFUNCTION and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">ACUTE RENAL FAILURE</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation and Handling</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span> to Immune Globulins</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 IgA Sensitive Patients with History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Renal Dysfunction/Failure</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  <span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, Increased Serum Viscosity, and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4  <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5  <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome (AMS)</a></h2>
<h2><a href="#section-5.6" class="toc">5.6  <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7  Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)</a></h2>
<h2><a href="#section-5.8" class="toc">5.8  Transmittable Infectious Agents </a></h2>
<h2><a href="#section-5.9" class="toc">5.9  Monitoring: Laboratory Tests</a></h2>
<h2><a href="#section-5.10" class="toc">5.10  Interference with Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_8a217480-c71c-4ea0-9964-97ee32d052f1"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">THROMBOSIS</span>, RENAL DYSFUNCTION and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">ACUTE RENAL FAILURE</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur with immune globulin products, including GAMMAGARD LIQUID.  Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors.  <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur in the absence of known risk factors. [see <span class="Italics">Warnings and Precautions(<a href="#ID_dc1aa7fc-a7db-4b39-8a77-0e868c0a0142">5.4</a>)</span>, <span class="Italics">Patient Counseling Information (<a href="#ID_32886639-1b02-45a1-b1a0-28388d71ee82">17</a>)</span>]</span></dd>
<dt>•</dt>
<dd><span class="Bold">Renal dysfunction, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur with immune globulin intravenous (IGIV) products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, age greater than 65, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="441532" conceptname="Monoclonal paraproteinemia">paraproteinemia</span>, or patients receiving known nephrotoxic drugs.  Renal dysfunction and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> occur more commonly in patients receiving IGIV products containing sucrose.  GAMMAGARD LIQUID does not contain sucrose.</span></dd>
<dt>•</dt>
<dd><span class="Bold">For patients at risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.  Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and assess blood viscosity in patients at risk of hyperviscosity. [see <span class="Italics">Dosage and Administration (<a href="#ID_0b356fd4-9302-467b-8832-297b18c1ebf6">2.3</a>)</span> and <span class="Italics">Warnings and Precautions (<a href="#ID_dc1aa7fc-a7db-4b39-8a77-0e868c0a0142">5.4</a>)</span>]</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_bd8ce6f8-5a04-48c6-817c-1bb343f93c37"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">GAMMAGARD LIQUID is indicated as replacement therapy for primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (PI) in adult and pediatric patients two years of age or older.  This includes, but is not limited to, common variable <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies<span class="Sup">1,2</span>.</p>
<p>GAMMAGARD LIQUID is indicated as a maintenance therapy to improve muscle strength and <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> in adult patients with <span class="product-label-link" type="condition" conceptid="4046338" conceptname="Motor neuropathy with multiple conduction block">Multifocal Motor Neuropathy</span> (MMN).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_7a2e8d3a-258e-4e42-9bb5-3c5b0ef5b05e"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_9283dbc9-9e61-4639-b5ef-79f9240b2351"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage</h2>
<table width="100%">
<caption><span>Table 1 Dosage and Administration </span></caption>
<col width="48%">
<col width="22%">
<col width="31%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Dose </span></p></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">Initial Infusion Rate</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Maintenance Infusion Rate</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="First"><span class="Bold">Intravenous Administration</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First">Primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">300 to 600 milligram/kg every 3 to 4 weeks based on clinical response</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">0.5 mL/kg/hr </p>
<p>(0.8 milligram/kg/min) for 30 minutes</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Increase every 30 minutes <br>(if tolerated) up to 5 mL/kg/hr (8 milligram/kg/min)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="product-label-link" type="condition" conceptid="4046338" conceptname="Motor neuropathy with multiple conduction block">Multifocal Motor Neuropathy</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Dose range 0.5 to 2.4 grams/kg/month based on clinical response (<a href="#ID_59aa7eee-d888-4633-9375-b94403d4fc00">14</a>)</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">0.5 mL/kg /hr </p>
<p>(0.8 milligram/kg/min)</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Infusion rate may be increased if tolerated up to 5.4 mL/kg/hr <br>(9 milligram/kg/min)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold"> Subcutaneous Administration</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First">Primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">
<p class="First">Initial Dose is 1.37 × previous intravenous dose divided by # of weeks between intravenous doses.<br></p>
<p>Maintenance dose is based on clinical response and target IgG trough level (<a href="#ID_7ee66650-e105-4338-a0a3-8100155179cc">2.2)</a>.</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Underline">40 kg BW and greater: </span> 30 mL/site at 20 mL/hr/site.</p>
<p><span class="Underline">Under 40 kg BW:</span><br>20 mL/site at 15 mL/hr/site.</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Underline">40 kg BW and greater: </span><br>30 mL/site at 20 to 30 mL/hr/site.</p>
<p><span class="Underline">Under 40 kg BW:</span><br>20 mL/site at 15 to 20 mL/hr/site.</p>
</td>
</tr>
</tbody>
</table>
<p class="First"><span class="Italics">Dose Adjustments for Intravenous Administration in Patients with PI</span></p>
<p>Adjust dose according to IgG levels and clinical response<span class="Bold">, </span>as the frequency and dose of immune globulin may vary from patient to patient. </p>
<p>No randomized controlled clinical trials are available to determine an optimum trough serum IgG level for intravenous treatment. If a patient misses a dose, administer the missed dose as soon as possible, and then resume scheduled treatments every 3 or 4 weeks, as applicable.</p>
<p>Prior to switching from intravenous to subcutaneous treatment, obtain the patient’s serum IgG trough level to guide subsequent dose adjustments. Start the initial subcutaneous dose approximately one week after the last intravenous infusion.</p>
<p><span class="Italics">Dose Adjustments for Intravenous Administration in MMN </span></p>
<p>The dose may need to be adjusted to achieve the desired clinical response.  In the clinical study, the dose ranged between 0.5 to 2.4 grams/kg/month (see Table 1).  While receiving GAMMAGARD LIQUID, 9% of subjects in the clinical study experienced neurological decompensation that required an increase in dose.  In order to avoid worsening of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in patients, dose adjustment may be necessary.</p>
<p><span class="Italics">Dose Adjustments for Subcutaneous Administration for PI only</span></p>
<p>Based on the results of clinical studies, the expected increase in serum IgG trough level while on weekly subcutaneous treatment, at the dose adjusted to provide a comparable AUC, is projected to be approximately 281 milligram/dL higher than the last trough level during prior stable intravenous treatment.  To calculate the target trough IgG level for subcutaneous treatment, add 281 milligram/dL to the IgG trough level obtained after the last intravenous treatment.</p>
<p>To guide dose adjustment, calculate the difference between the patient’s target serum IgG trough level and the IgG trough level during subcutaneous treatment.  Find this difference in the columns of Table 2 and the corresponding amount (in mL) by which to increase (or decrease) the weekly dose based on the patient's body weight.  If the difference between measured and target trough levels is less than 100 milligram/dL then no adjustment is necessary.  <span class="Bold">However, the patient's clinical response should be the primary consideration in dose adjustment</span>.</p>
<a name="_RefIDB1296803038D440DAF480231A31E68CB"></a><table width="100%">
<caption><span>Table 2 Change in Weekly Dose of GAMMAGARD LIQUID for Intended IgG Trough Level Adjustment<span class="Sup">a</span></span></caption>
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="13%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Difference between Measured and Target IgG Trough Levels </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Body Weight</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">100 mg/dL</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">200 mg/dL</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">300 mg/dL</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">400 mg/dL</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">19 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">28 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">38 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">60 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">34 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">45 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">70 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">26 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">53 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">45 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">60 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">90 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">34 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">51 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">68 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">19 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">38 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">57 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">75 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">110 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">21 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">42 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">62 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">83 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">120 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">45 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">68 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">91 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">130 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">49 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">74 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">98 mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">140 kg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">26 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">53 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">79 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">106 mL</p></td>
</tr>
</tbody>
</table>
<p>a	Derived using a linear approximation to the nomogram method with a slope of 5.3 kg/dL.</p>
<p>Example 1: A patient with a body weight of 80 kg has a measured IgG trough level of 800 milligram/dL and the target trough level is 1000 milligram/dL.  The desired target trough level difference is 200 milligram/dL (1000 milligram/dL minus 800 milligram/dL). The weekly dose of GAMMAGARD LIQUID should be <span class="Bold">increased<span class="Italics"></span></span>by 30 mL (3.0 gm).</p>
<p>Example 2: A patient with a body weight of 60 kg has a measured IgG trough of 1000 milligram/dL and the target trough level is 800 milligram/dL. The desired target trough level difference is 200 milligram/dL (800 milligram/dL minus 1000 milligram/dL). The weekly dose of GAMMAGARD LIQUID should be <span class="Bold">decreased<span class="Italics"></span></span>by 23 mL (2.3 gm).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_7ee66650-e105-4338-a0a3-8100155179cc"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation and Handling</h2>
<dl>
<dt>•</dt>
<dd>Inspect the drug product visually for particulate matter and discoloration prior to administration. GAMMAGARD LIQUID is a clear or slightly opalescent, colorless or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution.  Do not use if the solution is cloudy, turbid, or if it contains particulates.</dd>
<dt>•</dt>
<dd>GAMMAGARD LIQUID vial is for single use only.  Any vial that has been entered should be used promptly.  Partially used vials should be discarded.  GAMMAGARD LIQUID contains no preservative. </dd>
<dt>•</dt>
<dd>Allow refrigerated product to come to room temperature before use.  DO NOT MICROWAVE.  </dd>
<dt>•</dt>
<dd>Do not shake.</dd>
<dt>•</dt>
<dd>Do not mix with other products.</dd>
<dt>•</dt>
<dd>Do not use normal saline as a diluent. If dilution is desired, 5% dextrose in water (D5W) should be used as a diluent.</dd>
<dt>•</dt>
<dd>The infusion line may be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with normal saline. An in-line filter is optional.</dd>
<dt>•</dt>
<dd>Record the name and lot number of the product in the recipient's records.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0b356fd4-9302-467b-8832-297b18c1ebf6"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration</h2>
<p class="First"><span class="Italics">Intravenous </span></p>
<a name="_RefIDA7A367F800514915868C307842E2F43A"></a><table width="100%">
<caption><span>Table 3 Infusion Rates for Intravenous Administration </span></caption>
<col width="16%">
<col width="37%">
<col width="39%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">PI</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">MMN</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Initial</span></p></td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">0.5 mL/kg/hr </p>
<p>(0.8 milligram/kg/min) for 30 minutes </p>
</td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Increasing rates of infusion starting at 0.5 mL/kg/h (0.8 milligram/kg/min)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Subsequent</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Increase every 30 minutes <br>(if tolerated) up to 5 mL/kg/hr (8 milligram/kg/min)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Increasing to a maximum rate of 5.4 mL/kg /hr if tolerated (9 milligram/kg/min)</p></td>
</tr>
</tbody>
</table>
<p>Monitor patient vital signs throughout the infusion.  Certain adverse reactions such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and changes in pulse rate and blood pressure may be related to the rate of infusion.  Slow or stop infusion if adverse reactions occur.  If symptoms subside promptly, the infusion may be resumed at a lower rate that does not result in recurrence of the symptoms.</p>
<p>Adverse reactions may occur more frequently in patients receiving immune globulin for the first time, upon switching brands or if there has been a long interval since the previous infusion<span class="Sup">2</span>.  In such cases, start at lower infusion rates and gradually increase as tolerated. </p>
<p>Ensure that patients with pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> are not volume depleted.  For patients over 65 years of age or judged to be at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable.  In such cases, the maximal rate should be less than 3.3 milligram/kg/min (&lt;2mL/kg/hr), and consider discontinuation of administration if renal function deteriorates [see <span class="Italics">Warnings and Precautions </span>(<a href="#ID_3e0e9874-b2e7-4307-83ea-dec5918648ab">5.2</a>, <a href="#ID_dc1aa7fc-a7db-4b39-8a77-0e868c0a0142">5.4)</a> and <span class="Italics">Use In Specific Populations </span>(<a href="#ID_97a8d872-aec4-4b45-a9ab-7f450d48a63e">8.5</a>)].<br><span class="Italics">Subcutaneous for PI</span></p>
<a name="_RefIDFCB408ACB33E4048BDB56F8B8AE1971F"></a><table width="100%">
<caption><span>Table 4 Infusion Rates for Subcutaneous Administration </span></caption>
<col width="15%">
<col width="41%">
<col width="44%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">40 kg BW and greater</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Under 40 kg BW</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Initial</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">30 mL/site at a rate of 20 mL/hr/site</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 mL/site at a rate of 15 mL/hr/site</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Maintenance</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">30 mL/site at a rate of 20 to 30 mL/hr/site </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 mL/site at a rate of 15 to 20 mL/hr/site</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Selection of Infusion Site</span>: Suggested areas for subcutaneous infusion of GAMMAGARD LIQUID are abdomen, thighs, upper arms, or lower back. Infusion sites should be at least two inches apart, avoiding bony prominences.  Rotate sites each week.</p>
<p><span class="Underline">Volume per Site</span>: The weekly dose (mL) should be divided by 30 or 20, based on patient weight above, to determine the number of sites required.  Simultaneous subcutaneous infusion at multiple sites can be facilitated by use of a multi-needle administration set.</p>
<p><span class="Underline">Rate of Infusion for Patients 40 kg and greater (88 lbs)</span><span class="Italics">:</span> If multiple sites are used, the rate set on the pump should be the rate per site multiplied by the number of sites (e.g., 30 mL x 4 sites = 120 mL/hr).  The number of simultaneous sites should be limited to 8, or maximum infusion rate of 240 mL/hr.<br><span class="Underline"><br>Rate of Infusion for Patients under 40 kg (88 lbs)</span>: If multiple sites are used, the rate set on the pump should be the rate per site multiplied by the number of sites (e.g., 20 mL x 3 sites = 60 mL/hr).  The number of simultaneous sites should be limited to 8, or maximum infusion rate of 160 mL/hr.</p>
<p><span class="Underline">Instructions for Subcutaneous Administration:</span> Instruct patients to observe the following procedures:<br></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">1.  Aseptic technique </span>- Use aseptic technique when preparing and infusing GAMMAGARD LIQUID.</dd>
<dt> </dt>
<dd>
<span class="Bold">2.  Assemble supplies</span> - Set up a clean work area and gather all supplies necessary for the subcutaneous infusion: vial(s) of GAMMAGARD LIQUID, ancillary supplies, sharps container and pump. If GAMMAGARD LIQUID has already been pooled into a bag or a syringe, skip to Step 5.</dd>
<dt> </dt>
<dd>
<span class="Bold">3.  Product preparation</span> - Remove the protective cap from the vial to expose the center of the vial. Wipe the stopper with an alcohol pad and allow to dry.</dd>
</dl>
<div class="Figure">
<a name="id894"></a><img alt="Remove the protective cap from the vial to expose the center of the vial. Wipe the stopper with an alcohol pad and allow to dry" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-01.jpg">
</div>
<dl>
<dt> </dt>
<dd>
<span class="Bold">4.  Withdraw GAMMAGARD LIQUID from the vials</span> - Attach a sterile syringe to a needle and draw air into the syringe barrel equal to the amount of product to be withdrawn. Inject the air into the vial and withdraw the desired volume of GAMMAGARD LIQUID. If multiple vials are required to achieve the desired dose, repeat this step.</dd>
</dl>
<div class="Figure">
<a name="id899"></a><img alt="Attach a sterile syringe to a needle and draw air into the syringe barrel equal to the amount of product to be withdrawn. Inject the air into the vial and withdraw the desired volume of GAMMAGARD LIQUID. If multiple vials are required to achieve the desired dose, repeat this step." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-02.jpg">
</div>
<dl>
<dt> </dt>
<dd>
<span class="Bold">5.  Prepare the infusion pump and tubing </span>- Follow the manufacturer’s instructions for preparing the pump and administration tubing, if needed. Be sure to prime the pump tubing to ensure that no air is left in the tubing and needle.</dd>
<dt> </dt>
<dd>
<span class="Bold">6.  Select the infusion sites</span> - Select the number of infusion sites depending on the volume of the total dose.  See Administration<span class="Italics"><a href="#ID_0b356fd4-9302-467b-8832-297b18c1ebf6">(2.3)</a></span> for recommended maximum volumes and rates. Potential sites for infusion include the back of arms, abdomen, thighs, and lower back (see Figure below).  Ensure sites are at least 2 inches apart; avoid bony prominences. </dd>
</dl>
<div class="Figure">
<a name="id909"></a><img alt="Select the number of infusion sites depending on the volume of the total dose.  See administration for recommended maximum volumes and rates. Potential sites for infusion include the back of arms, abdomen, thighs, and lower back (see Figure below).  Ensure sites are at least 2 inches apart; avoid bony prominences." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-03.jpg">
</div>
<dl>
<dt> </dt>
<dd>
<span class="Bold">7.  Cleanse the infusion site(s)</span> - Cleanse the infusion site(s) with an antiseptic skin preparation (e.g., alcohol pad) using a circular motion working from the center of the site and moving to the outside. Allow to dry.</dd>
</dl>
<div class="Figure">
<a name="id913"></a><img alt="Cleanse the infusion site(s) with an antiseptic skin preparation (e.g., alcohol pad) using a circular motion working from the center of the site and moving to the outside. Allow to dry." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-04.jpg">
</div>
<dl>
<dt> </dt>
<dd>
<span class="Bold">8.  Insert the needle</span> - Choose the correct needle length to assure that GAMMAGARD LIQUID is delivered into the subcutaneous space.  Grasp the skin and pinch at least one inch of skin between two fingers.   Insert needle at a 90-degree angle with a darting motion into the subcutaneous tissue.  Secure the needle.</dd>
</dl>
<div class="Figure">
<a name="id917"></a><img alt="Choose the correct needle length to assure that GAMMAGARD LIQUID is delivered into the subcutaneous space.  Grasp the skin and pinch at least one inch of skin between two fingers.   Insert needle at a 90 degree angle with a darting motion into the subcutaneous tissue.  Secure the needle." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-05.jpg">
</div>
<dl>
<dt> </dt>
<dd>
<span class="Bold">9.  Check for proper needle placement</span> - Prior to the start of infusion, check each needle for correct placement to make sure that a blood vessel has not been punctured. Gently pull back on the attached syringe plunger and monitor for any blood return in the needle set.  If you see any blood, remove and discard the needle set. Repeat priming and needle insertion steps in a different infusion site with a new needle set.</dd>
</dl>
<div class="Figure">
<a name="id921"></a><img alt="Prior to the start of infusion, check each needle for correct placement to make sure that a blood vessel has not been punctured.  Gently pull back on the attached syringe plunger and monitor for any blood return in the needle set." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-06.jpg">
</div>
<dl>
<dt> </dt>
<dd>
<span class="Bold">10. Secure the needle to the skin</span> - Secure the needle(s) in place by applying a sterile protective dressing over the site.</dd>
</dl>
<div class="Figure">
<a name="id925"></a><img alt="Secure the needle(s) in place by applying a sterile protective dressing over the site." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-07.jpg">
</div>
<dl>
<dt> </dt>
<dd>
<span class="Bold">11. Start infusion of GAMMAGARD LIQUID</span> - Follow the manufacturer’s instructions to turn pump on.</dd>
<dt> </dt>
<dd>
<span class="Bold">12. Document the infusion</span> - Remove the peel-off label with product lot number and expiration date from the GAMMAGARD LIQUID vial and place in treatment diary/log book to keep track of the product lots used. Keep the treatment diary/log book current by recording the time, date, dose, product label and any reactions after each infusion.</dd>
<dt> </dt>
<dd>
<span class="Bold">13. Remove needle set - </span>After the infusion is complete, remove the needle set and gently press a small piece of gauze over the needle insertion site and cover with a protective dressing.  Discard any unused solution and disposable supplies in accordance with local requirements.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_b0d5b92d-43df-4c67-80a1-83454b167dea"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">GAMMAGARD LIQUID is an aqueous solution containing 10% IgG (100 milligram/mL).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_8088d771-b7bc-40fe-b61c-4c01305bae19"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_f8f63805-a63c-4519-8e30-13cf654d2803"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span> to Immune Globulins</h2>
<p class="First">GAMMAGARD LIQUID is contraindicated in patients who have a history of anaphylactic or severe systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to the administration of human immune globulin.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_54a4bb16-597d-4bd4-a8e2-2506a36cba43"></a><a name="section-4.2"></a><p></p>
<h2>4.2 IgA Sensitive Patients with History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">GAMMAGARD LIQUID is contraindicated in IgA-deficient patients with antibodies to IgA and a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported with the intravenous use of GAMMAGARD LIQUID and is theoretically possible following subcutaneous administration [see <span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span> (<a href="#ID_91d0bc6c-2dce-410a-88e1-d1892dac88f1">5.1)]</a>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_5352b7a2-11a7-4592-baef-8207696910c0"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_91d0bc6c-2dce-410a-88e1-d1892dac88f1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may occur, even in patients who had tolerated previous treatment with human normal immune globulin.  In case of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, discontinue GAMMAGARD LIQUID infusion immediately and institute appropriate treatment.  </p>
<p>GAMMAGARD LIQUID contains trace amount of IgA (average concentration of 37μg/mL).  Patients with antibodies to IgA have a greater risk of developing potentially severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.  GAMMAGARD LIQUID is contraindicated in patients with antibodies against IgA and a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> <br>[<span class="Italics">see Contraindications (<a href="#ID_8088d771-b7bc-40fe-b61c-4c01305bae19">4)</a></span>].     </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_3e0e9874-b2e7-4307-83ea-dec5918648ab"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Renal Dysfunction/Failure</h2>
<p class="First">Acute renal dysfunction/failure, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span>, proximal tubular <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span>, osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur upon use of IGIV treatment, especially those containing sucrose<span class="Sup">3</span>.  Acute renal dysfunction/failure has been reported in association with infusions of GAMMAGARD LIQUID.  Assure that patients are not volume depleted prior to the initiation of infusion of GAMMAGARD LIQUID. In patients who are at risk of developing renal dysfunction, because of pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or predisposition to <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> (such as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, age greater than 65, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="441532" conceptname="Monoclonal paraproteinemia">paraproteinemia</span>, or patients receiving known nephrotoxic drugs, etc.), administer GAMMAGARD LIQUID intravenously at the minimum rate of infusion practicable (not exceeding 3.3 milligram IgG/kg/min (&lt;2 mL/kg/hr) [see <span class="Italics">Dosage and Administration (<a href="#ID_0b356fd4-9302-467b-8832-297b18c1ebf6">2.3)</a>]</span>. </p>
<p>Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk for developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.  Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of GAMMAGARD LIQUID and again at appropriate intervals thereafter.  If renal function deteriorates, consider discontinuation of GAMMAGARD LIQUID [see<span class="Italics"> Dosage and Administration (<a href="#ID_7a2e8d3a-258e-4e42-9bb5-3c5b0ef5b05e">2.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_fcce5a1f-7b34-4b41-a502-d906e584fa82"></a><a name="section-5.3"></a><p></p>
<h2>5.3  <span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, Increased Serum Viscosity, and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, increased serum viscosity and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in patients receiving GAMMAGARD LIQUID.  It is critical to distinguish true <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> from a pseudohyponatremia that is temporally or causally related to <span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">hyperproteinemia</span> with concomitant decreased calculated serum <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> or elevated osmolar gap; because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, a further increase in serum viscosity, and a predisposition to <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span><span class="Sup">4</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_dc1aa7fc-a7db-4b39-8a77-0e868c0a0142"></a><a name="section-5.4"></a><p></p>
<h2>5.4  <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur following treatment with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors.  <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur in the absence of known risk factors.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies.  For patients at risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable.  Ensure adequate hydration in patients before administration.  Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and assess blood viscosity in patients at risk for hyperviscosity </span>[see <span class="Italics">Boxed Warning,Dosage and Administration (<a href="#ID_0b356fd4-9302-467b-8832-297b18c1ebf6">2.3</a>), Patient Counseling Information (<a href="#ID_32886639-1b02-45a1-b1a0-28388d71ee82">17</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_f7824ad1-be23-4e6b-904a-0595c71e83bb"></a><a name="section-5.5"></a><p></p>
<h2>5.5  <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome (AMS)</h2>
<p class="First">AMS may occur with IGIV treatment, and has been reported with intravenous use of  GAMMAGARD LIQUID. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae. The syndrome usually begins within several hours to two days following IGIV treatment.</p>
<p>AMS is characterized by the following signs and symptoms: severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">nuchal rigidity</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, painful eye movements, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> [<span class="Italics">see Patient Counseling Information <a href="#ID_32886639-1b02-45a1-b1a0-28388d71ee82">(17)]</a>.</span> Cerebrospinal fluid (CSF) studies frequently reveal <span class="product-label-link" type="condition" conceptid="4240184" conceptname="Pleocytosis">pleocytosis</span> up to several thousand cells per mm<span class="Sup">3</span>, predominantly from the granulocytic series, and elevated protein levels up to several hundred milligram/dL, but negative culture results.  Conduct a thorough neurological examination on patients exhibiting such symptoms and signs, including CSF studies, to rule out other causes of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. </p>
<p>AMS may occur more frequently with high dose (2 grams/kg) IGIV treatment and/or rapid infusion of IGIV.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_45fc3bce-c890-4fda-a97c-f5b6ff182990"></a><a name="section-5.6"></a><p></p>
<h2>5.6  <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></h2>
<p class="First">GAMMAGARD LIQUID, contains blood group antibodies that may act as hemolysins and induce <span class="Italics">in vivo </span>coating of red blood cells (RBC) with immune globulin.  This may cause a positive direct antiglobulin test [DAT (Coomb’s test)]<span class="Sup">5-6</span>.  Delayed <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> can develop subsequent to GAMMAGARD LIQUID therapy due to enhanced RBC sequestration; acute <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, consistent with <span class="product-label-link" type="condition" conceptid="4049138" conceptname="Intravascular hemolysis">intravascular hemolysis</span>, has been reported <span class="Italics">[</span>see<span class="Italics"> Adverse Reactions </span><br><span class="Italics">(<a href="#ID_ad1647f5-1d24-4940-a1ac-82a2e1a423e5">6</a>)]</span><span class="Sup">5-8</span>.</p>
<p>The following risk factors may be related to the development of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>: high doses (e.g., ≥2 grams/kg, single administration or divided over several days) and non-O blood group.<span class="Sup">5</span>  Underlying inflammatory state in an individual patient may increase the risk of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span><span class="Sup">5</span> but its role is uncertain<span class="Sup">8,9</span>. </p>
<p>Monitor patients for clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> <span class="Italics">[see Warnings and Precautions<a href="#ID_27af433e-bcd5-4825-a091-56b4ef69d24b">(5.9</a>)]</span>, particularly patients with risk factors noted above.   Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 to 96 hours post infusion. If clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> or a significant drop in hemoglobin or hematocrit have been observed, perform additional confirmatory laboratory testing. If transfusion is indicated for patients who develop <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> with clinically compromising <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_c3ffdc21-4ded-4610-901d-3abb1a0f07a1"></a><a name="section-5.7"></a><p></p>
<h2>5.7  Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)</h2>
<p class="First">Non-cardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>) has been reported in patients following treatment with IGIV products, including GAMMAGARD LIQUID.  <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is characterized by severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, normal left ventricular function, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.  Symptoms typically occur within 1 to 6 hours after treatment.</p>
<p>Monitor patients for pulmonary adverse reactions [<span class="Italics">see Patient Counseling Information <a href="#ID_32886639-1b02-45a1-b1a0-28388d71ee82">(17)]</a></span>. If <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is suspected, perform appropriate tests for the presence of anti-neutrophil and anti-HLA antibodies in both the product and patient serum.  <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> may be managed using oxygen therapy with adequate ventilatory support.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_e4d1e232-a733-47f6-b9a8-0e4af345a6f3"></a><a name="section-5.8"></a><p></p>
<h2>5.8  Transmittable Infectious Agents </h2>
<p class="First">Because GAMMAGARD LIQUID is made from human blood and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent. This also applies to unknown or emerging viruses and other pathogens. No confirmed cases of viral transmission or vCJD have been associated with GAMMAGARD LIQUID.</p>
<p>All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician to possibly have been transmitted by this product should be reported by the physician or other healthcare provider to Baxter Healthcare Corporation, at 1-800-423-2862 (in the U.S.).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_27af433e-bcd5-4825-a091-56b4ef69d24b"></a><a name="section-5.9"></a><p></p>
<h2>5.9  Monitoring: Laboratory Tests</h2>
<dl>
<dt>•</dt>
<dd>Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Assess renal function, including measurement of BUN and serum creatinine, before the initial infusion of GAMMAGARD LIQUID and at appropriate intervals thereafter.</dd>
<dt>•</dt>
<dd>Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span><span class="Sup">3,4</span>.</dd>
<dt>•</dt>
<dd>If signs and/or symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> are present after an infusion of GAMMAGARD LIQUID, perform appropriate laboratory testing for confirmation.</dd>
<dt>•</dt>
<dd>If <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and patient’s serum.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_bfa84295-4f1d-4575-aaf9-ac62b8b650c3"></a><a name="section-5.10"></a><p></p>
<h2>5.10  Interference with Laboratory Tests</h2>
<p class="First">After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield false positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_ad1647f5-1d24-4940-a1ac-82a2e1a423e5"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"><span class="Underline">PI: Intravenous</span>:  The serious adverse reaction seen during intravenous treatment in the clinical trials for PI was <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>.  The most common adverse reactions for PI (observed in ≥5% of subjects) were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">oedema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">cardiac murmur</span>.  </p>
<p><span class="Underline">Subcutaneous</span>: No serious adverse reactions were observed during the clinical trial for subcutaneous treatment.  The most common adverse reactions during subcutaneous treatment (observed in ≥5% of PI subjects) were infusion site (local) event, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4109301" conceptname="Increased systolic arterial pressure">blood pressure systolic increased</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>.</p>
<p><span class="Underline">MMN</span>: The serious adverse reactions in the clinical trial for MMN were <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.  The most common adverse reactions for MMN (observed in ≥5% of subjects) were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_cfaf8128-6c37-466e-ad71-b01b284c3fa8"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><span class="Italics">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice</span>. </p>
<p><span class="Italics">PI: Intravenous Administration</span></p>
<p>The safety of GAMMAGARD LIQUID intravenous infusion was evaluated in 61 subjects<span class="Sup">10</span>.  </p>
<p>Fifteen adverse reactions in 8 subjects were serious.  Of these, two episodes of <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> in one patient were deemed possibly related to the infusion of GAMMAGARD LIQUID.  </p>
<p>There were 400 non-serious adverse reactions.  Of these, 217 were rated as mild (transient <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that resolves spontaneously or with minimal intervention), 164 were rated as moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae), and 19 were rated as severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). All of the severe non-serious adverse experiences were transient, did not lead to hospitalization, and resolved without complication.  One subject withdrew from the study due to a non-serious adverse experience (<span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">papular rash</span>). </p>
<p>Adverse reactions with a frequency of ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 5.</p>
<a name="_RefID95ADDCDB02EC40C5A516F3A35094087B"></a><table width="100%">
<caption><span>Table 5 Adverse Reactions Occurring in ≥5% of Subjects  </span></caption>
<col width="25%">
<col width="27%">
<col width="41%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Events</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">By Infusion N (%)</span></p>
<p><span class="Bold">(N=1812 Infusions)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">By Subject N (%)</span></p>
<p><span class="Bold">(N=61 Subjects)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">94 (5.2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">29 (47.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">33 (1.8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">14 (23.0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">28 (1.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17 (27.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17 (0.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11 (18.0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">14 (0.8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8 (13.1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">14 (0.8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8 (13.1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13 (0.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7 (11.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12 (0.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9 (14.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12 (0.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (6.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11 (0.6%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8 (13.1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11 (0.6%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9 (14.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9 (0.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8 (13.1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9 (0.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (8.2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7 (0.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6 (9.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7 (0.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (8.2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6 (0.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (6.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (0.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (6.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (0.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (8.2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Oedema peripheral</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (0.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (8.2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (0.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (6.6%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">Cardiac murmur</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (0.2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (6.6%)</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">PI: Subcutaneous Administration</span></p>
<p>The safety of GAMMAGARD LIQUID in subcutaneous infusion was evaluated in 47 subjects<span class="Sup">11</span>. </p>
<p>Adverse reactions with a frequency of ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 6.</p>
<a name="_RefID252C6863044B4088A14782F2025E9B66"></a><table width="100%">
<caption><span>Table 6 Adverse Reactions Occurring in ≥5% of Subjects </span></caption>
<col width="31%">
<col width="31%">
<col width="31%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Events</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">By Infusion N (%) </span></p>
<p><span class="Bold">(N=2294 infusions)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">By Subject N (%) </span></p>
<p><span class="Bold">(N=47 Subjects)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Infusion site (local) event</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">55 (2.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">21 (44.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">31 (1.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">19 (40.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11 (0.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7 (14.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">Heart rate increased</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11 (0.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11 (0.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9 (19.1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9 (0.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (10.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7 (0.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7 (0.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (10.6%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6 (0.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (8.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4109301" conceptname="Increased systolic arterial pressure">Blood pressure systolic increased</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6 (0.3%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (0.2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Ear pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (0.2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">Aphthous stomatitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (0.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (0.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (0.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.4%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (0.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.4%)</p></td>
</tr>
</tbody>
</table>
<p>Of the 348 non-serious ARs, 228 were rated as mild (transient <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that resolves spontaneously or with minimal intervention), 112 were rated as moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae), and 8 were rated as severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae).  Neither of the severe ARs required hospitalization or resulted in sequelae.</p>
<p><span class="Underline">Local AEs:</span> Local AEs reported as mild (transient <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that resolves spontaneously or with minimal intervention) were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and irritation.  Local AEs reported as mild or moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae) were <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>.</p>
<p>One subject withdrew from the study after 10 treatments with GAMMAGARD LIQUID subcutaneous infusion (2.5 months) due to increased <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p>The overall rate of local ARs (excluding <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>) during the subcutaneous treatment periods was 2.4% per infusion.  In subcutaneous naïve patients, the incidence of local ARs (N=1757 infusions) was 2.8% (2.2% mild and 0.6% moderate with no severe AEs).  In the subjects who were subcutaneous experienced (N=537 infusions), the incidence of local AEs was 1.1% (1.1% mild, and no moderate or severe AEs). </p>
<p>In the clinical study after all subcutaneous doses were adjusted, all subjects but one reached their maximum rate allowed in the protocol, 20 mL/site/hour if weight was below 40 kg and 30/mL/hour for weight 40 kg and greater, for one or more of the infusions. 70% (31 of 44) of these subjects opted for the highest rate for all infusions.  No subject restricted the rate due to an AR. In the clinical study, median duration of each weekly infusion was 1.2 hours (range: 0.8–2.3 hours) after all subcutaneous doses were adjusted. The rate set on the pump was that rate per site multiplied by the number of sites, with no maximum.  </p>
<p>During all subcutaneous treatment periods, 99.8% of infusions were completed without a reduction, interruption, or discontinuation for tolerability reasons.  The proportion of subjects who experienced local ARs (excluding <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>) was highest immediately following the switch from intravenous to subcutaneous treatment in all age groups.  The rate of all local ARs per infusion immediately after switching from intravenous to subcutaneous treatment was 4.9% (29/595), decreasing to 1.5% (8/538) by the end of the study and to 1.1% (10/893) in the Study Extension.  Over subsequent subcutaneous infusions, there was a decrease of local ARs.</p>
<p>Eight (17%) subjects experienced a local adverse reaction during the first infusion, but that decreased to 1 (2.2%) for the subsequent infusions, ranging from 0 to 4 (8.7%) during the first year of subcutaneous treatment.  No subject reported a local adverse reaction from week 53 to end of study at week 68.</p>
<p><span class="Italics">MMN: Intravenous Infusion</span></p>
<p>The safety of GAMMAGARD LIQUID was evaluated in 44 subjects with MMN who received a total of 983 infusions. Two serious adverse reactions, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> occurred. </p>
<p>In the study, among the 317 non-serious AEs, 176 were considered ARs.  Of these, 126 were mild (transient <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that resolves spontaneously or with minimal intervention), 37 were moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae) and 13 were severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae).  </p>
<p>Adverse reactions with a frequency of ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 7.</p>
<a name="_RefIDE59333E60AF04367ABC10FCE50CFDF4E"></a><table width="100%">
<caption><span>Table 7 Adverse Reactions Occurring in ≥5% of MMN Subjects </span></caption>
<col width="18%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Events</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">GAMMAGARD LIQUID</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">By Infusion</span></p>
<p><span class="Bold">N (%)</span></p>
<p><span class="Bold">(N=983 Infusions)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">By Subject</span></p>
<p><span class="Bold">N (%)</span></p>
<p><span class="Bold">(N=44 Subjects)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">By Infusion</span></p>
<p><span class="Bold">N (%)</span></p>
<p><span class="Bold">(N=129 Infusions)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">By Subject</span></p>
<p><span class="Bold">N (%)</span></p>
<p><span class="Bold">(N=43 Subjects)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">28 (2.85%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">14 (31.82%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (2.33%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2 (4.65%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest Discomfort</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (0.31%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.82%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0 (0.00%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0 (0.00%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Spasms</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (0.31%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.82%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0 (0.00%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0 (0.00%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscular weakness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (0.41%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.82%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1 (0.78%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1 (2.33%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">28 (2.85%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.82%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2 (1.55%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1 (2.33%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (0.41%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.82%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0 (0.00%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0 (0.00%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 (0.41%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (6.82%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1 (0.78%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1 (2.33%)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_3bba60fc-8f12-4e87-9a00-601269eb36a1"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Postmarketing Experience</h2>
<p class="First"><span class="Italics">Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.</span></p>
<a name="_RefID5823B81B65A14B879E79E2AC501DF9DF"></a><table width="100%">
<caption><span>Intravenous ADRs </span></caption>
<col width="42%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold"> Hematologic </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"> Infusion Reactions </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"> Neurological </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Transient ischemic attack, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"> Cardiovascular  </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"> Respiratory  </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, oxygen saturation decreased</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"> Gastrointestinal  </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"> Integumentary </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold"> Psychiatric </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></p></td>
</tr>
</tbody>
</table>
<p>In addition to the events listed above which were observed for GAMMAGARD LIQUID, the following events have been identified for IGIV products in general:</p>
<table width="100%">
<col width="43%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Renal</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Osmotic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Respiratory </span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">Cyanosis</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Integumentary</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4309632" conceptname="Epidermolysis">epidermolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Cardiovascular</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Neurological</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Bold">Hematologic</span></p>
<p><span class="Bold">Gastrointestinal</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span></p>
<p>Hepatic dysfunction</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_5bc60e17-40fa-4360-ae59-93b87a2c6429"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Passive transfer of antibodies may transiently impair the immune responses to live attenuated virus vaccines such as <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span> and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> for up to 6 months and for a year or more to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> (rubeola).  Inform the immunizing physician of recent therapy with GAMMAGARD LIQUID so that appropriate precautions can be taken <span class="Italics">[see Patient Counseling Information (<a href="#ID_32886639-1b02-45a1-b1a0-28388d71ee82">17</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_7a750df9-faf5-49ff-883a-6cad5fb69f5f"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_ac7cefcf-a776-4f95-abd8-9fc39fb52a35"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with GAMMAGARD LIQUID.  It is also not known whether GAMMAGARD LIQUID can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Immune globulins cross the placenta from maternal circulation increasingly after 30 weeks of gestation.  GAMMAGARD LIQUID should be given to a pregnant woman only if clearly indicated.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_5053a26a-5c3e-4161-be39-f4dcff4fef6f"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether GAMMAGARD LIQUID is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when GAMMAGARD LIQUID is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_87451984-1dc5-476d-88ec-f96983f3d6a5"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><span class="Italics">PI</span></p>
<p>GAMMAGARD LIQUID administered intravenously was evaluated in 15 pediatric subjects with PI (7 were 2 to &lt;12 years old and 8 were 12 to &lt;16) in a multicenter clinical study. GAMMAGARD LIQUID administered subcutaneously was evaluated in 18 pediatric subjects with PI (14 were 2 to &lt;12 years old and 4 were 12 to &lt;16) in another multicenter clinical study.  The safety and efficacy profiles were similar to adult subjects.  No pediatric-specific dose requirements were necessary to achieve the desired serum IgG levels.</p>
<p>Safety and efficacy of GAMMAGARD LIQUID in pediatric patients below the age of 2 have not been established. </p>
<p><span class="Italics">MMN</span></p>
<p>Safety and effectiveness in pediatric patients with MMN have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_97a8d872-aec4-4b45-a9ab-7f450d48a63e"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><span class="Italics">PI</span></p>
<p>Limited information is available for the geriatric use of GAMMAGARD LIQUID. GAMMAGARD LIQUID administered intravenously and subcutaneously was evaluated in two PI studies with a total of 8 subjects over the age of 65 years.  No differences in safety or efficacy were observed for this group.  Monitor patients who are at an increased risk for developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> or thrombotic events. Do not exceed the recommended dose, and infuse at the minimum intravenous infusion rate practicable [see <span class="Italics">Boxed Warning, Warnings and Precautions <a href="#ID_3e0e9874-b2e7-4307-83ea-dec5918648ab">(5.2</a>, <a href="#ID_dc1aa7fc-a7db-4b39-8a77-0e868c0a0142">5.4)</a> and Dosage and Administration <a href="#ID_0b356fd4-9302-467b-8832-297b18c1ebf6">(2.3</a>)]</span>.</p>
<p><span class="Italics">MMN</span></p>
<p>GAMMAGARD LIQUID was administered intravenously for treatment of MMN in 5 subjects 65 years and above.  There were insufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects [see <span class="Italics">Boxed Warning, Warnings and Precautions <a href="#ID_3e0e9874-b2e7-4307-83ea-dec5918648ab">(5.2</a>, <a href="#ID_dc1aa7fc-a7db-4b39-8a77-0e868c0a0142">5.4)</a> and Dosage and Administration (<a href="#ID_0b356fd4-9302-467b-8832-297b18c1ebf6">2.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_a61f45e7-3d6a-47ec-8795-83c67d6bae8a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">With intravenous administration, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of GAMMAGARD LIQUID may lead to <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> and hyperviscosity.  Patients at risk of complications of <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> and hyperviscosity include elderly patients and those with cardiac or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_f1fe3259-379e-46b1-92d6-a7a48ebac94a"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">GAMMAGARD LIQUID is a ready-for-use sterile, liquid preparation of highly purified and concentrated <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> (IgG) antibodies.  The distribution of the IgG subclasses is similar to that of normal plasma.  The Fc and Fab functions are maintained in GAMMAGARD LIQUID.  Pre-kallikrein activator activity is not detectable.  GAMMAGARD LIQUID contains 100 milligram/mL protein.  At least 98% of the protein is immune globulin, the average immunoglobulin A (IgA) concentration is 37 μg/mL, and immunoglobulin M is present in trace amounts.  GAMMAGARD LIQUID contains a broad spectrum of IgG antibodies against bacterial and viral agents.  Glycine (0.25M) serves as a stabilizing and buffering agent, and there are no added sugars, sodium or preservatives.  The pH is 4.6 to 5.1.  The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> is 240 to 300 mOsmol/kg, which is similar to physiological <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> (285 to 295 mOsmol/kg). GAMMAGARD LIQUID is manufactured from large pools of human plasma.  IgG preparations are purified from plasma pools using a modified Cohn-Oncley <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> ethanol fractionation process, as well as cation and anion exchange chromatography.</p>
<p>Screening against potentially infectious agents begins with the donor selection process and continues throughout plasma collection and plasma preparation.  Each individual plasma donation used in the manufacture of GAMMAGARD LIQUID is collected only at FDA approved blood establishments and is tested by FDA licensed serological tests for <span class="product-label-link" type="condition" conceptid="4318957" conceptname="Hepatitis B surface antigen">Hepatitis B Surface Antigen</span> (HBsAg), and for antibodies to Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV-1/HIV-2) and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus (HCV) in accordance with U.S. regulatory requirements.  As an additional safety measure, mini-pools of the plasma are tested for the presence of HIV-1 and HCV by FDA licensed Nucleic Acid Testing (NAT) and found to be negative.  </p>
<p>To further improve the margin of safety, validated virus inactivation/removal steps have been integrated into the manufacturing and formulation processes, namely solvent/detergent (S/D) treatment<span class="Sup">12</span>, 35 nm nanofiltration, and a low pH incubation at elevated temperature (30°C to 32°C).  The S/D process includes treatment with an organic mixture of tri-n-butyl phosphate, octoxynol 9 and polysorbate 80 at 18°C to 25°C for a minimum of 60 minutes.  S/D treatment inactivates the lipid-enveloped viruses investigated to below detection limits within minutes<span class="Sup">12</span>.</p>
<p><span class="Italics">In vitro</span> virus spiking studies have been used to validate the capability of the manufacturing process to inactivate and remove viruses.  To establish the minimum applicable virus clearance capacity of the manufacturing process, these virus clearance studies were performed under extreme conditions (e.g., at minimum S/D concentrations, incubation time and temperature for the S/D treatment).  </p>
<p>Virus clearance studies for GAMMAGARD LIQUID performed in accordance with good laboratory practices are summarized in Table 8.</p>
<a name="_RefIDE3BBC7E8C10B494484097E4123A796CF"></a><table width="100%">
<caption><span>Table 8 Three Dedicated Independent Virus Inactivation/Removal Steps Mean Log<span class="Sub">10</span> Reduction Factors<span class="Sup">a</span> (RFs) For Each Virus and Manufacturing Step </span></caption>
<col width="14%">
<col width="15%">
<col width="11%">
<col width="10%">
<col width="15%">
<col width="9%">
<col width="10%">
<col width="16%">
<tbody class="Headless">
<tr class="First Toprule">
<td class="Lrule Toprule" align="center"><p class="First"><span class="Bold">Virus type</span></p></td>
<td class="Toprule" align="center" colspan="3">
<p class="First"><span class="Bold">Enveloped</span></p>
<p><span class="Bold">RNA</span></p>
</td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Enveloped DNA</span></p></td>
<td class="Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">Non-enveloped </span></p>
<p><span class="Bold">RNA</span></p>
</td>
<td class="Rrule Toprule" align="center">
<p class="First"><span class="Bold">Non-enveloped </span></p>
<p><span class="Bold">DNA</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Family</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Retroviridae</span></p></td>
<td class="Botrule" align="center" colspan="2"><p class="First"><span class="Bold">Flaviviridae</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Herpesviridae</span></p></td>
<td class="Botrule" align="center" colspan="2"><p class="First"><span class="Bold">Picornaviridae</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Parvoviridae</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Virus</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">HIV-1</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">BVDV</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">WNV</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">PRV</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">HAV</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">EMCV</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">MMV</span></p></td>
</tr>
<tr>
<td class="Lrule Toprule" align="center"><p class="First"><span class="Bold">SD treatment</span></p></td>
<td class="Toprule" align="center"><p class="First">&gt;4.5</p></td>
<td class="Toprule" align="center"><p class="First">&gt;6.2</p></td>
<td class="Toprule" align="center"><p class="First">n.a.</p></td>
<td class="Toprule" align="center"><p class="First">&gt;4.8</p></td>
<td class="Toprule" align="center"><p class="First">n.d.</p></td>
<td class="Toprule" align="center"><p class="First">n.d.</p></td>
<td class="Rrule Toprule" align="center"><p class="First">n.d</p></td>
</tr>
<tr>
<td class="Lrule" align="center"><p class="First"><span class="Bold">35 nm nanofiltration</span></p></td>
<td align="center"><p class="First">&gt;4.5</p></td>
<td align="center"><p class="First">&gt;5.1</p></td>
<td align="center"><p class="First">&gt; 6.2</p></td>
<td align="center"><p class="First">&gt;5.6</p></td>
<td align="center"><p class="First">5.7</p></td>
<td align="center"><p class="First">1.4</p></td>
<td class="Rrule" align="center"><p class="First">2.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Low pH treatment</span></p></td>
<td class="Botrule" align="center"><p class="First">&gt;5.8</p></td>
<td class="Botrule" align="center"><p class="First">&gt;5.5</p></td>
<td class="Botrule" align="center"><p class="First">&gt; 6.0</p></td>
<td class="Botrule" align="center"><p class="First">&gt;6.5</p></td>
<td class="Botrule" align="center"><p class="First">n.d.<span class="Sup">b</span></p></td>
<td class="Botrule" align="center"><p class="First">&gt; 6.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Overall log reduction factor (ORF)</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">&gt;14.8</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">&gt;16.8</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">&gt;12.2</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">&gt;16.9</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">5.7<span class="Sup">b</span></span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">&gt;7.7</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">5.1</span></p></td>
</tr>
<tr class="Botrule Last"><td class="Botrule Lrule Rrule Toprule" colspan="8"><p class="First">Abbreviations: HIV-1, Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus Type 1; BVDV, Bovine Viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Virus (model for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus and other lipid enveloped RNA viruses); WNV, West Nile Virus; PRV, Pseudorabies Virus (model for lipid enveloped DNA viruses, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus); EMCV, Encephalomyocarditis Virus (model for non-lipid enveloped RNA viruses, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A virus [HAV]); MMV, Mice Minute Virus (model for non-lipid enveloped DNA viruses, including B19 virus [B19V]); n.d. (not done), n.a. (not applicable).</p></td></tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>
<span class="Sup">a</span>	For the calculation of these RF data from virus clearance study reports, applicable manufacturing conditions were used.  Log<span class="Sub">	10</span>	 RFs on the order of 4 or more are considered effective for virus clearance in accordance with the Committee for Medicinal Products for Human Use (CHMP, formerly CPMP) guidelines.</dd>
<dt> </dt>
<dd>
<span class="Sup">b</span>	No RF obtained due to immediate neutralization of HAV by the anti-HAV antibodies present in the product</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_9d90d804-529a-492a-ae2e-18bee6a09281"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_76cd289a-7455-4c67-a996-17e15f377ae6"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">GAMMAGARD LIQUID supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.  GAMMAGARD LIQUID also contains a spectrum of antibodies capable of interacting with and altering the activity of cells of the immune system as well as antibodies capable of reacting with cells such as erythrocytes.  The role of these antibodies and the mechanisms of action of IgG in GAMMAGARD LIQUID have not been fully elucidated.  </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_70a206cd-6136-454a-86eb-d9b0169c86f1"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">PI: Intravenous Administration</span></p>
<p>Following intravenous infusion, IGIV products show a biphasic decay curve.  The initial (α) phase is characterized by an immediate post-infusion peak in serum IgG and is followed by rapid decay due to equilibration between the plasma and extravascular fluid compartments.  The second (β) phase is characterized by a slower and constant rate of decay.  The commonly cited “normal? half-life of 18 to 25 days is based on studies in which tiny quantities of radiolabeled IgG are injected into healthy individuals.  When radiolabeled IgG was injected into patients with <span class="product-label-link" type="condition" conceptid="440072" conceptname="Hypogammaglobulinemia">hypogammaglobulinemia</span> or agammaglobulinemia, highly variable half-lives ranging from 12 to 40 days were observed.  In other radiolabeled studies, high serum concentrations of IgG, and <span class="product-label-link" type="condition" conceptid="4242214" conceptname="Hypermetabolism">hypermetabolism</span> associated with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, have been seen to coincide with a shortened half-life of IgG.</p>
<p>In contrast, however, pharmacokinetic studies in immunodeficient patients are based on the decline of IgG concentrations following infusions of large quantities of immune globulin.  In such trials, investigators have reported uniformly prolonged half-lives of 26 to 35 days.  Pharmacokinetic parameters for GAMMAGARD LIQUID were determined from total IgG levels following the fourth infusion in 61 subjects with primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> treated intravenously with the product every 3 or 4 weeks according to the regimen used prior to entering the study.  Of these, 57 had sufficient pharmacokinetic data to be included in the dataset.  The median weight-adjusted dose per subject was 455 milligram/kg/4 weeks with a range of 262 to 710.  Pharmacokinetic parameters are presented in Table 9.</p>
<a name="_RefIDFCF1F52E211E4D52A0B738B9A37E1FBD"></a><table width="100%">
<caption><span>Table 9 Summary of Intravenous Pharmacokinetic Parameters in 57 Subjects </span></caption>
<col width="43%">
<col width="24%">
<col width="32%">
<tbody class="Headless">
<tr class="First Toprule">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Median</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">95% Confidence Interval</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Dose of IgG (milligram/kg/4 weeks)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">455</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Range:  262-710</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Elimination Half-Life ( T ½ days)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">35</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(31, 42)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">AUC<span class="Sub">0-21d</span> (milligram·days/dL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">29139</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(27494, 30490)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">C<span class="Sub">max</span>  (Peak, milligram/dL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2050</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(1980, 2200)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">C<span class="Sub">min</span>  (Trough, milligram/dL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1030</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(939, 1110)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Incremental recovery (milligram/dL)/(milligram/kg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(2.2, 2.6)</p></td>
</tr>
<tr class="Botrule Last"><td class="Botrule Lrule Rrule Toprule" colspan="3">
<p class="First">Abbreviations: AUC = area under the curve;</p>
<p>C<span class="Sub">max</span> = maximum concentration; C<span class="Sub">min</span> = minimum concentration.</p>
</td></tr>
</tbody>
</table>
<p>Median IgG trough levels were maintained between 960 to 1120 milligram/dL.  These dosing regimens maintained serum trough IgG levels generally considered adequate to prevent <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  The elimination half-life of GAMMAGARD LIQUID of 35 days was similar to the half-lives reported for other IGIV products.</p>
<p><span class="Italics">PI: Subcutaneous Administration</span></p>
<p>Pharmacokinetic (PK) parameters of subcutaneously administered GAMMAGARD LIQUID were evaluated in subjects with primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> (PI) who were 12 years and older during a clinical study <span class="Italics">[see Clinical Studies (<a href="#ID_59aa7eee-d888-4633-9375-b94403d4fc00">14</a>)]</span>.  Subjects were treated intravenously for 12 weeks with GAMMAGARD LIQUID and then switched to weekly subcutaneous GAMMAGARD LIQUID infusions.  Initially, all subjects were treated for a minimum of 12 weeks at a subcutaneous dose that was 130% of the intravenous dose.  A comparison of the area under the curve (AUC) for intravenous and subcutaneous infusions done on the first 15 adult subjects determined that the subcutaneous dose required to provide an exposure from subcutaneous administration that was not inferior to the exposure from intravenous administration was 137% of the intravenous dose.  Subsequently, all subjects were treated with this dose for 6 weeks after which the dose was individualized for all subjects using the trough IgG levels, as described below.  After a minimum of 8 weeks at this subcutaneous dose, the PK evaluation was conducted on 32 subjects 12 years of age or older.</p>
<p>The mean adjusted dose at the end of the study was 137.3% (125.7 to 150.8) of the intravenous dose for subjects 12 years and older, and 141.0% (100.5 to 160.0) for subjects under the age of 12.  Thus, there was not a significant dosing difference required for children.  At this dose adjustment, the geometric mean ratio of the AUC for subcutaneous vs. intravenous GAMMAGARD LIQUID administration was 95.2% (90% confidence limit 92.3 to 98.2).The peak IgG level occurred 2.9 (1.2 to 3.2) days after subcutaneous administration.  </p>
<p>The pharmacokinetic parameters of GAMMAGARD LIQUID administered intravenously compared to subcutaneously in the clinical trial are shown in Table 10.  The mean peak IgG levels were lower (1393 ± 289 milligram/dL) during subcutaneous treatment with GAMMAGARD LIQUID compared to when it was administered intravenously (2240 ± 536 milligram/dL), consistent with the lower weekly dose compared to the dose administered every 3 or 4 weeks intravenously.  In contrast, the mean trough levels were higher with GAMMAGARD LIQUID given subcutaneously (1202 ± 282 milligram/dL), compared to those when given intravenously (1050 ± 260 milligram/dL), a result of both higher monthly dose and more frequent dosing.  The median IgG trough level during intravenous treatment in this clinical trial, 1010 milligram/dL (95% CI: 940 to 1240), was similar to the median value of 1030 milligram/dL (95% CI: 939 to 1110) during the intravenous clinical trial shown above in Table 9.  By contrast, the median trough IgG level during subcutaneous treatment for the study was higher, at 1260 milligram/dL (95% CI: 1060 to 1400).</p>
<a name="_RefID4D1B9E8D65D6499B841A54D36E573D3C"></a><table width="100%">
<caption><span>Table 10 Pharmacokinetic Parameters of Subcutaneously Administered GAMMAGARD LIQUID Compared to GAMMAGARD LIQUID Administered Intravenously </span></caption>
<col width="52%">
<col width="21%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"> </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Subcutaneous Administration</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Intravenous Administration</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Number of Subjects</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">32</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">32</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Dose (milligram/kg)<br>    Mean ±SD<br>    Range (min to max)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">182.6 ± 48.4</p>
<p>94.2 to 293.8</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">133.2 ± 36.9</p>
<p>62.7 to 195.4</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">IgG Peak Levels (milligram/dL)<br>    Mean ± SD<br>    Range (min to max)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1393 ± 289<br>734 to 1900</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2240 ± 536<br>1130 to 3610</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">IgG Trough Levels (milligram/dL)<br>    Mean ± SD<br>    Range (min to max)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1202 ± 282<br>621 to 1700</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1050 ± 260<br>532 to 1460</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">AUC<span class="Sup">b</span>(days*milligram/dL)<br>    Mean ± SD<br>    Range (min to max)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9176 ± 1928<br>4695 to 12468</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9958 ± 2274<br>5097 to 13831</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Clearance [mL/kg/day]<br>    Mean ± SD   <br>    Range (min to max)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">2.023 ± 0.528</p>
<p>1.225 to 3.747</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.355 ± 0.316<br>0.880 to 2.340</p></td>
</tr>
</tbody>
</table>
<p>a	Weekly equivalent dose<br>	b	Standardized to a 7 day interval</p>
<p><span class="Italics">MMN: Intravenous Administration </span></p>
<p>No full pharmacokinetic study was conducted in patients with MMN.  However, trough levels of IgG were measured in this patient population (n = 44; five 12 week study parts).  The median serum trough level of total IgG over all study parts regardless of dosing intervals and length of infusion cycles, was 16.40 g/L (95% confidence interval: 15.7 to 17.1).  During placebo administration, the median trough level was 12.35 g/L (95% CI: 10.6 to 13.6).  The relationship between serum IgG concentration and efficacy was not assessed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_59aa7eee-d888-4633-9375-b94403d4fc00"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><span class="Italics">PI: Intravenous Administration</span></p>
<p>Intravenous use of GAMMAGARD LIQUID is supported by a study in 61 subjects who were treated with 300 to 600 milligram/kg every 21 to 28 days for 12 months.  The age range of the subjects was between 6 to 72 years: 54% female and 46% male, and 93% Caucasian, 5% African-American, and 2% Asian.  Three subjects were excluded from the per-protocol analysis due to non-study product related reasons.  The annualized rate of specified acute serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>, i.e., the mean number of specified acute serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> per subject per year was studied (see <a href="#_RefID70B76D39B1424536AA6C623B55EBA831">Table 11</a>).</p>
<a name="_RefID70B76D39B1424536AA6C623B55EBA831"></a><table width="100%">
<caption><span>Table 11 Summary of Validated Acute Serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span> for the Per-Protocol Analysis </span></caption>
<col width="73%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Number of </span><br><span class="Bold">Events</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Validated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span><span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span> / <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">Bacterial Meningitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">Osteomyelitis</span> / <span class="product-label-link" type="condition" conceptid="80482" conceptname="Suppurative arthritis">Septic Arthritis</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Visceral <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Total</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Hospitalizations Secondary to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Mean Number of Validated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> per Subject per Year</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> p-value<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">p &lt; 0.0001</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> 95% Confidence Interval<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">(0.000, 0.064)</p></td>
</tr>
</tbody>
</table>
<p>a	Serious acute <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> were defined by FDA and met specific diagnostic requirements.<br>	b	The rate of validated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was compared with a rate of 1 per subject per year, in accordance with recommendations by the FDA Blood Products Advisory Committee.</p>
<p>The annualized rate of other specified validated <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> (see Table 12), and the number of hospitalizations secondary to all validated infectious complications were also studied (see Table 11 and Table 12).</p>
<a name="_RefID2DE1FFF4EE3D48568CD2A445074A6513"></a><table width="100%">
<caption><span>Table 12 Summary of Validated Other <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span> </span></caption>
<col width="80%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Number of Events</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Validated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span><span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infection</span>: <span class="product-label-link" type="condition" conceptid="4028970" conceptname="Tracheobronchitis">Tracheobronchitis</span>, <span class="product-label-link" type="condition" conceptid="4165112" conceptname="Bronchiolitis">Bronchiolitis</span> (Without Evidence of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infection</span>:<br> Other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (e.g., <span class="product-label-link" type="condition" conceptid="257010" conceptname="Abscess of lung">Lung Abscess</span>, <span class="product-label-link" type="condition" conceptid="4209859" conceptname="Empyema">Empyema</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Total</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Hospitalizations Secondary to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Mean Number of Validated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> per Subject per Year</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.07</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> 95% Confidence Interval </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(0.018, 0.168)</p></td>
</tr>
</tbody>
</table>
<p>a	Other <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> that met specific diagnostic requirements</p>
<p>None of the 61 treated subjects were positive for HCV, HIV-1, and HIV-2 and HBV prior to study entry and none converted from negative to positive during the 12-month period.</p>
<p><span class="Italics">PI: Subcutaneous (SC) Administration</span></p>
<p>A prospective, open-label, non-controlled, multi-center study was conducted in the US to determine the efficacy, tolerability and PK of GAMMAGARD LIQUID subcutaneous infusion in 49 adult and pediatric subjects with PID.  All subjects were treated for 12 weeks with GAMMAGARD LIQUID intravenous infusion every 3 or 4 weeks.  Subjects who were on intravenous treatment prior to entering the study were switched to GAMMAGARD LIQUID at the same dose and frequency.  Subjects who were receiving subcutaneous immune globulin were switched to GAMMAGARD LIQUID at the intravenous dose they had been given prior to switching to subcutaneous treatment.  A PK analysis was performed at the end of the intravenous period in all subjects aged 12 years and older.</p>
<p>One week after the last intravenous infusion, each subject began subcutaneous treatment with GAMMAGARD LIQUID at 130% of the weekly equivalent of the intravenous dose for a minimum of 12 weeks.  PK data from the first 15 adult subjects were used to determine the dose required to ensure that the IgG exposure with subcutaneous treatment was not inferior to that with intravenous treatment.  The median dose determined from these subjects was 137% of the intravenous dose, and subsequently all subjects were treated for a minimum of 6 weeks at this dose.  After 6 subcutaneous infusions, a trough IgG level was obtained and used to individually adapt the subcutaneous dose of GAMMAGARD LIQUID to compensate for individual variation from the mean value of 137% [<span class="Italics">see Pharmacokinetics (<a href="#ID_70a206cd-6136-454a-86eb-d9b0169c86f1">12.3)</a> and Dosage and Administration <a href="#ID_9283dbc9-9e61-4639-b5ef-79f9240b2351">(2.1</a></span>)].  All subjects received a minimum of 12 infusions at this individually adapted dose.  All subjects continued to receive subcutaneous treatment with GAMMAGARD LIQUID until the last subject completed the study.  There were 47 subjects treated with 2,294 subcutaneous infusions of GAMMAGARD LIQUID: 4 subjects treated for up to 29 weeks, 17 subjects for 30 to 52 weeks, and 26 subjects for 53 weeks or longer.  The median duration of subcutaneous treatment was 379 days (range: 57 to 477 days). </p>
<p>Efficacy was determined throughout the entire subcutaneous phase. There were 31 adults 16 years or older, 4 adolescents between 12 and &lt;16 years of age, and 14 children between 2 years and &lt;12.  The volume of GAMMAGARD LIQUID infused was 30 mL per site for patients weighing 40 kg and greater, and 20 mL per site for those weighing less than 40 kg.  The total weekly dose was divided by those values to determine the number of sites.</p>
<p>Mean weekly subcutaneous doses ranged from 181.9 milligram/kg to 190.7 milligram/kg (at 130% to 137% of the intravenous dose).  In the study, the number of infusion sites per infusion was dependent on the dose of IgG and ranged from 2 to 10.  In 75% of infusions, the number of infusion sites was 5 or fewer.</p>
<p>There were 3 serious validated <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>, all bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. None of these subjects required hospitalization to treat their <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The annual rate of acute serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> while on GAMMAGARD LIQUID subcutaneous treatment was 0.067, with an upper 99% confidence limit of 0.133, which is lower than the minimal goal of achieving a rate of &lt;1 <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> per patient-year. </p>
<p>The summary of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and associated events for subjects during subcutaneous treatment with GAMMAGARD LIQUID is summarized in Table 13.  The annual rate of any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in this study during subcutaneous treatment, including viral and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, was 4.1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> per subject per year.</p>
<a name="_RefID563E10A301664D1694CDFF4700100607"></a><table width="100%">
<caption><span>Table 13 Summary of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and Associated Events </span></caption>
<col width="44%">
<col width="44%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Number of subjects (efficacy phase) </p>
<p>Total number of subject years </p>
<p>Annual rate of any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </p>
</td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">47</p>
<p>44</p>
<p>4.1 (95% CI 3.2 to 5.1)</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>/subject year</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">Antibiotic use<span class="Sup">a</span> (prophylaxis or treatment)</p>
<p>Number of subjects (%) </p>
<p>Annual rate</p>
</td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">40 (85.1%)</p>
<p>50.2 (95% CI 33.4 to 71.9) </p>
<p>days/subject year</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">Days out of work/school/day care or unable to perform normal activities</p>
<p>Number of subjects (%)</p>
<p>Annual rate</p>
</td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">25 (53.2%)</p>
<p>4.0 (95% CI 2.5 to 6.1) </p>
<p>days/subject year</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Hospitalizations due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></p>
<p>Number of subjects (%)</p>
<p>Annual rate</p>
</td>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">0 (0.0%)</p>
<p>0.0 (95% CI 0.0 to 0.1) </p>
<p>days/subject year</p>
</td>
</tr>
</tbody>
</table>
<p>a	Included systemic and topical antibacterial, anti-fungal, anti-viral, and anti-protozoal antimicrobials.</p>
<p><span class="Italics">MMN:</span></p>
<p>A randomized withdrawal, double-blind, placebo controlled, cross-over study was conducted to evaluate the efficacy and safety/tolerability of GAMMAGARD LIQUID in 44 adult subjects with MMN. The study examined grip strength in the more affected hand<span class="Sup">13</span> (measured with dynamometer), and Guy’s Neurological <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Scale (GNDS) [upper limb part 6 subsection]<span class="Sup">14</span>. Study subjects were on a regimen of licensed Immunoglobulin (existing maintenance dose ranging from 0.5 to 2.0 grams/kg/month) prior to enrollment. The clinical trial was an enrichment design, therefore the results cannot be generalized to naïve patients. Each subject completed a five part, 12-week study parts (3 stabilization phases, one randomized withdrawal and one cross-over period). Open-label GAMMAGARD LIQUID was administered for 12 weeks at the beginning and end of the study for clinical stabilization, and between the double-blinded periods to prevent carry-over effect. If, during either of the double-blinded treatment period, the subject’s upper limb function involving the affected muscles deteriorated, such that the subject had difficulty completing daily activities or the subject experienced a decline in grip strength of ≥50% in the more affected hand, the subject was switched directly to the next stabilization phase of open-label GAMMAGARD LIQUID (“accelerated switch?) without breaking the blind.</p>
<p>All subjects were treated for 12 weeks with GAMMAGARD LIQUID during the initial stabilization (Stabilization-1) phase. In the cross-over 1 period, each subject was then randomized to either withdrawal from GAMMAGARD LIQUID to placebo or continue GAMMAGARD LIQUID for a period of 12 weeks and then transferred to stabilization phase 2. Subjects that did not tolerate the treatment during the double-blind cross-over period were immediately transferred to open label GAMMAGARD LIQUID stabilization phase 2. Following Stabilization phase 2, the subjects were assigned to a second double-blind treatment for 12 weeks to either placebo or GAMMAGARD LIQUID depending on randomization received in cross-over period 1. No subject was allowed to experience placebo more than one time during the clinical study. Following this period the subjects were further stabilized for 12 weeks on open-label GAMMAGARD LIQUID, stabilization phase 3.</p>
<p>Sixty nine percent (n=29) required an accelerated switch to open-label treatment with GAMMAGARD LIQUID during the placebo period due to functional deterioration, but did not switch when receiving GAMMAGARD LIQUID. The median treatment days for treatment with GAMMAGARD LIQUID was 84 days and the median treatment days for the placebo was 28 days. Only one subject (2.4%) switched to open‑label treatment during blinded GAMMAGARD LIQUID cross-over period 1 but did not switch during placebo administration (p &lt;0.001).</p>
<p>Forty-four subjects were evaluated to demonstrate effectiveness of GAMMAGARD LIQUID to improve or maintain muscle strength and functional ability in patients with MMN.</p>
<p>Statistical significance in favor of GAMMAGARD LIQUID over placebo was demonstrated by a substantially lower decline from baseline (22.30%; 95% CI: 9.92% to 34.67%) in the mean grip strength in the more affected hand following treatment (see Table 14). The difference in relative change for GAMMAGARD LIQUID and placebo of 22.94% (95% CI: 10.69 to 35.19) was statistically significant (p &lt;0.001).</p>
<a name="_RefIDC7C5D83C2D574360A196272860AE68A8"></a><table width="100%">
<caption><span>Table 14 Relative Change in Grip Strength in the More Affected Hand during Cross-over Period (ANOVA) (mIntent-to-Treat Dataset) No. of subjects (N=41) </span></caption>
<col width="10%">
<col width="18%">
<col width="18%">
<col width="12%">
<col width="18%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Statistics</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Sequence 1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Sequence 2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Difference</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">GAMMAGARD LIQUID</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">GAMMAGARD LIQUID</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">(GAMMAGARD LIQUID - Placebo)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">41</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Mean (SD)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><br>-16.36 (32.84)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-30.52 (29.68)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-29.19 (39.95)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.46 <br>(10.72)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">22.30<br> (39.21)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Median</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-3.90</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-27.00</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-25.03</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-0.11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">26.6</p></td>
</tr>
</tbody>
</table>
<p>Guy’s Neurological <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Scores (GNDS)<span class="Sup">14</span> for the upper limbs, reflecting both fine motor skills and proximal strength, showed a significant difference in efficacy between GAMMAGARD LIQUID and placebo at the 2.5% level in favor of GAMMAGARD LIQUID. GNDS is a patient orientated clinical <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> scale designed for <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> and is considered appropriate for other neurological disorders.</p>
<p>As determined by GNDS scores for the upper limbs, 35.7% of subjects deteriorated while receiving the placebo, but not during treatment with GAMMAGARD LIQUID whereas 11.9% of subjects deteriorated during GAMMAGARD LIQUID but not over the placebo period. This difference was statistically significant (p=0.021) (see Table 15). 4.8% of subjects showed deterioration with both placebo and GAMMAGARD LIQUID, while 47.6% showed no deterioration on either.</p>
<a name="_RefIDDCE8FFE0E87D4E778B3B3EEE230F43FF"></a><table width="100%">
<caption><span>Table 15 McNemar's Test for Subjects with Deterioration in Guy's Neurological <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Score (Intent-to-Treat Dataset) No. of subjects (N=42) </span></caption>
<col width="47%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Deterioration on Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">15 (35.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Deterioration on GAMMAGARD LIQUID</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (11.9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Deterioration on both</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2 (4.8%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">No deterioration</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 (47.6%)</p></td>
</tr>
</tbody>
</table>
<p>When data from both treatment sequences were combined, a relative decline of ≥30% in grip strength in the more affected hand occurred in 42.9% of subjects during the placebo period, but not during treatment with GAMMAGARD LIQUID. 4.8% of subjects experienced a ≥30% decline during treatment with GAMMAGARD LIQUID, but not during placebo. A relative decline of ≥30% in grip strength in the less affected hand occurred in 31.0% of subjects during the placebo period, but not during treatment with GAMMAGARD LIQUID. No subject experienced a ≥30% decline during treatment with GAMMAGARD LIQUID. </p>
<p>The Overall <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Sum Score (ODSS) changed by -7.14% during placebo (indicating worsening of <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>), and by -1.11% (indicating minimal change in <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>) during treatment with GAMMAGARD LIQUID. For this specific analysis of ODSS, lower scores represented more <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.</p>
<p>With the dominant hand, subjects required 17% longer to complete the 9-hole peg test (a measure of dexterity) at the end of the placebo period compared to baseline. By contrast, at the end of the GAMMAGARD LIQUID treatment period, subjects required 1.2% longer to complete the 9-hole peg test for the dominant hand compared to baseline. With the non-dominant hand, subjects required 33% longer to complete the 9-hole peg test at the end of the placebo period and and 6.7% longer at the end of the GAMMAGARD LIQUID treatment period compared to baseline.</p>
<p>Compared to baseline, patients’ assessment of physical functioning, as measured by visual analog scale (VAS), showed a mean change of 290% during placebo compared to baseline. Patient’s assessments of physical functioning showed a mean change of 73% during GAMMAGARD LIQUID treatment. Higher visual analog scale scores represent more severe <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_971410ec-843a-4e94-b460-eab60a83e285"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson Jr. RP, Patel DD, Secord E, Sorenson RU, Wasserman RL, Cunningham-Rundles C, Use of Intravenous Immunoglobulin in Human Disease: A Review of Evidence by Members of the Primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Committee of the American Academy of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, and Immunology. <span class="Italics">J <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Clin Immunol</span> 2006; 117:S525-53.</dd>
<dt>2.</dt>
<dd>Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al.  Practice parameter for the diagnosis and management of primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>.  <span class="Italics">Ann <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> Immunol</span>. 2005; 94(suppl 1):S1-63.</dd>
<dt>3.</dt>
<dd>Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin.  <span class="Italics">Transfusion Med Rev.</span> 2003;17:241-251.</dd>
<dt>4.</dt>
<dd> Katz U, Sheonfeld Y.  Review: intravenous immunoglobulin therapy and thromboembolic complications.  <span class="Italics">Lupus</span> 2005;14:802-8.</dd>
<dt>5.</dt>
<dd>Wilson JR, Bhoopalam N, Fisher M. <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> associated with intravenous immunoglobulin. <span class="Italics">Muscle Nerve</span> 1997;20:1142-1145.</dd>
<dt>6.</dt>
<dd>Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. <span class="Italics">J Autoimmun</span> 1999;13:129-135.   </dd>
<dt>7.</dt>
<dd>Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, et al. Hemolytic <span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">transfusion reactions</span> after administration of intravenous immune (gamma) globulin: a case series analysis. <span class="Italics">Transfusion.</span> 2008; 48:1598-601.</dd>
<dt>8.</dt>
<dd>Copelan EA, Strohm PL, Kennedy MS, Tuschka PJ, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> following intravenous immune globuline therapy. <span class="Italics">Transfusion </span>1986;26:410-412.</dd>
<dt>9.</dt>
<dd> Kahwaji J, et al.; Acute <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> after High-Dose Intravenous Immunoglobin Therapy in Highly HLA Sensitized Patients. <span class="Italics">Clin J Am Soc Nephrol</span>; 2009 (4):1993-97.</dd>
<dt>10.</dt>
<dd>Church JA, Leibl H, Stein MR, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>. <span class="Italics">J Clin Immunol</span> 2006;26 (4):388-395.</dd>
<dt>11.</dt>
<dd>Wasserman RL, Melamed I, Kobrinski L, et al. Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Disease. <span class="Italics">J Clin Immunol</span> 2011.</dd>
<dt>12.</dt>
<dd>Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. <span class="Italics">Transfusion</span> 2003;43:1023-1028.</dd>
<dt>13.</dt>
<dd>Shechtman O, Gestewitz L, Kimble C. Reliability and validity of the DynEx dynamometer. <span class="Italics">J. Hand Ther.</span> 2005;18:339-347.</dd>
<dt>14.</dt>
<dd>Sharrack B, Hughes RA. The Guy's Neurological <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Scale (GNDS): a new <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> measure for <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>. <span class="Italics">Mult. Scler.</span> 1999;5:223-233.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_467780d9-aac0-43e4-aa26-665b53e4e946"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING </h1>
<p class="First">GAMMAGARD LIQUID is supplied in single use bottles containing the labeled amount of functionally active IgG.  The packaging of this product is not made with natural rubber latex.</p>
<p>The following presentations of GAMMAGARD LIQUID are available:</p>
<table width="100%">
<col width="24%">
<col width="21%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">NDC Number</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Volume</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Grams Protein</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0944-2700-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0944-2700-03</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0944-2700-04</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">50 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0944-2700-05</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">100 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0944-2700-06</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">200 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0944-2700-07</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">300 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30.0</p></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd><span class="Bold">Do not freeze.</span></dd>
<dt>•</dt>
<dd>Store GAMMAGARD LIQUID in the refrigerator or at room temperature. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Refrigeration: </span>2° to 8°C [36° to 46°F] for up to 36 months. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Room Temperature: </span>up to25°C [77°F] for up to 24 months. </dd>
<dt>•</dt>
<dd>Expiration dates for both storage conditions are printed on the outer carton and vial label.</dd>
<dt>•</dt>
<dd>Do not use past the applicable expiration date.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_32886639-1b02-45a1-b1a0-28388d71ee82"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA approved patient labeling (Information for Patients and Instructions for Use for PI patients only). Inform patients to immediately report the following signs and symptoms to their healthcare provider:</p>
<dl>
<dt>•</dt>
<dd>Decreased urine output, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>/<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and/or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> [<span class="Italics">see Warnings and Precautions <a href="#ID_3e0e9874-b2e7-4307-83ea-dec5918648ab">(5.2</a></span>)].</dd>
<dt>•</dt>
<dd>Instruct patients to immediately report symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.  These symptoms may include <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and/or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that worsens on deep breathing, unexplained rapid pulse, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of the body. [see<span class="Italics"> Warnings and Precautions (<a href="#ID_dc1aa7fc-a7db-4b39-8a77-0e868c0a0142">5.4</a>)</span>].</dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">neck stiffness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, sensitivity to light, painful eye movements, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see Warnings and Precautions <a href="#ID_f7824ad1-be23-4e6b-904a-0595c71e83bb">(5.5)</a>].</span>
</dd>
<dt>•</dt>
<dd>Increased heart rate, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, yellowing of the skin or eyes, and dark-colored urine <span class="Italics">[see Warnings and Precautions <a href="#ID_45fc3bce-c890-4fda-a97c-f5b6ff182990">(5.6)</a>].</span>
</dd>
<dt>•</dt>
<dd>Trouble breathing, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, blue lips or extremities, or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> that can occur 1 to 6 hours after an infusion of GAMMAGARD LIQUID [<span class="Italics">see Warnings and Precautions (<a href="#ID_c3ffdc21-4ded-4610-901d-3abb1a0f07a1">5.7</a>)]</span>.</dd>
</dl>
<p>Prior to starting GAMMAGARD LIQUID ask about a history of <span class="product-label-link" type="condition" conceptid="433171" conceptname="Selective immunoglobulin A deficiency">IgA deficiency</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to immune globulin or other blood products.  Patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> should not be treated subcutaneously at home until several treatments have been administered and tolerated under medical supervision.  </p>
<p>Inform patients that GAMMAGARD LIQUID is made from human plasma and may contain infectious agents that can cause disease (e.g., viruses and, theoretically, the vCJD agent).  The risk of GAMMAGARD LIQUID transmitting an infectious agent has been reduced by screening plasma donors for prior exposure, testing donated plasma, and inactivating or removing certain viruses during manufacturing.  Patients should report any symptoms that concern them which might be caused by virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> [see <span class="Italics">Warnings and Precautions<a href="#ID_e4d1e232-a733-47f6-b9a8-0e4af345a6f3"> (5.8)</a>]</span>.</p>
<p>Inform patients that GAMMAGARD LIQUID can interfere with their immune response to live viral vaccines such as <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span> and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and instruct patients to notify their healthcare professional of this potential interaction when they are receiving vaccinations <span class="Italics">[see Drug Interactions  <a href="#ID_5bc60e17-40fa-4360-ae59-93b87a2c6429">(7</a>)].</span></p>
<p><span class="Italics">Subcutaneous (SC) Administration Only</span></p>
<p><span class="Bold">Self-administration </span>– If self-administration is deemed to be appropriate by the physician, clear instructions and training on subcutaneous infusion should be given to the patient/caregiver, and the demonstration of their ability to independently administer subcutaneous infusions should be documented.</p>
<dl>
<dt>•</dt>
<dd>Ensure the patient understands the importance of <span class="Italics">consistent</span> weekly subcutaneous infusion to maintain appropriate steady IgG levels.</dd>
<dt>•</dt>
<dd>Instruct the patient to keep a treatment diary/log book.  This diary/log book should include information about each infusion such as, the time, date, dose, lot number(s) and any reactions.</dd>
<dt>•</dt>
<dd>Inform the patient that mild to moderate local infusion-site reactions (e.g., <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>) are a common side effect of subcutaneous treatment, but to contact their healthcare professional if a local reaction increases in severity or persists for more than a few days.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_f8265e89-c734-4877-b496-5eba3e9ca901"></a><a name="section-16"></a><p></p>
<h1>Patient package insert</h1>
<p class="First"><span class="Bold">Information For Patients</span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">Immune Globulin Infusion (Human) 10%</span></p>
<p><span class="Bold">For Intravenous and Subcutaneous Administration</span></p>
<p><span class="Bold">Information for Patients</span></p>
<p>The following summarizes important information about GAMMAGARD LIQUID. Please read it carefully before using this medicine. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about GAMMAGARD LIQUID. If you have any questions after reading this, ask your healthcare provider.</p>
<p><span class="Bold">What is the most important information I need to know about GAMMAGARD LIQUID?</span></p>
<p>GAMMAGARD LIQUID can cause the following serious reactions:</p>
<dl>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> causing difficulty in breathing or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> </dd>
<dt>•</dt>
<dd>Decreased kidney function or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> </dd>
<dt>•</dt>
<dd>Blood clots in the heart, brain, lungs or elsewhere in the body </dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, painful eye movements, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>•</dt>
<dd>Dark colored urine, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> </dd>
</dl>
<p><span class="Bold">What is GAMMAGARD LIQUID?</span></p>
<p>GAMMAGARD LIQUID is a ready-to-use, liquid medicine that contains <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> (IgG) antibodies, which protect the body against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<p>GAMMAGARD LIQUID is used to treat patients with primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> diseases (PI) and patients with <span class="product-label-link" type="condition" conceptid="4046338" conceptname="Motor neuropathy with multiple conduction block">multifocal motor neuropathy</span> (MMN).</p>
<p>There are many forms of PI.  The most common types of PI result in an inability to make a very important type of protein called antibodies, which help the body fight off <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> from bacteria or viruses. GAMMAGARD LIQUID is made from human plasma that is donated by healthy people.  GAMMAGARD LIQUID contains antibodies collected from these healthy people that replace the missing antibodies in PI patients.</p>
<p>MMN is a rare disease that causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> that worsens over time.  It affects the strength of the lower parts of  arms and hands more than the legs, usually without affecting the touch sensation.</p>
<p><span class="Bold">Who should not use GAMMAGARD LIQUID?</span></p>
<p>Do not use GAMMAGARD LIQUID if you have a known history of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to immune globulin or other blood products.  If you have such a history, discuss this with your healthcare provider to determine if GAMMAGARD LIQUID can be given to you.  Tell your healthcare provider if you have a condition called selective (or severe) immunoglobulin A (IgA) deficiency.</p>
<p><span class="Bold">How should I use GAMMAGARD LIQUID? </span></p>
<p>GAMMAGARD LIQUID is given into a vein (intravenously) or under the skin (subcutaneously).  For patients with PI, infusions into the vein are usually given every 3 or 4 weeks whereas infusions under the skin are given every week.  For patients with MMN, infusions are given into a vein every 2 to 4 weeks as ordered by your physician.  You and your healthcare provider will decide which way is best for you.  Most of the time infusions under the skin are given at home by patients or caregivers.  Although it is possible to give yourself infusions into the vein at home they are more often given in a hospital or infusion center by a nurse.</p>
<p>Instructions for giving GAMMAGARD LIQUID under the skin (subcutaneously) are provided in the Instructions for Use brochure.  Only use GAMMAGARD LIQUID by yourself after you have been instructed by your healthcare provider.</p>
<p><span class="Bold">What should I avoid while taking GAMMAGARD LIQUID?</span></p>
<p>GAMMAGARD LIQUID can make vaccines (like <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>/<span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>/<span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span> or <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> vaccines) not work as well for you.  Before you get any vaccines, tell your healthcare provider that you take GAMMAGARD LIQUID.</p>
<p>Tell your healthcare provider if you are pregnant, or plan to become pregnant, or if you are nursing.</p>
<p><span class="Bold">What are the possible or reasonably likely side effects of GAMMAGARD LIQUID?</span></p>
<p>The following one or more possible reactions may occur at the site of infusion.  These generally go away within a few hours, and are less likely after the first few infusions. </p>
<table width="100%">
<col width="32%">
<col width="35%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd>Mild or moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Redness</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span></dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd>Warmth</dd>
</dl></td>
</tr>
</tbody>
</table>
<p>During the infusion of GAMMAGARD LIQUID, look out for the first signs of the following common side effects:</p>
<table width="100%">
<col width="31%">
<col width="36%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>/<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Shaking</span> <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd>Faster Heart Rate</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper Abdominal Pain</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">Increased Blood Pressure</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span></dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>/tightness</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore throat</span></dd>
</dl></td>
</tr>
</tbody>
</table>
<p>If any of the following problems occur after starting treatment with GAMMAGARD LIQUID, stop the infusion immediately and contact your healthcare provider or call emergency services. These could be signs of a serious problem.</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the mouth or throat, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, trouble breathing, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. These could be signs of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</dd>
<dt>•</dt>
<dd>Bad <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiff neck</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and sensitivity to light.  These could be signs of irritation of the lining around your brain.</dd>
<dt>•</dt>
<dd>Reduced urination, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your legs.  These could be signs of a kidney problem. </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, warmth, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or a lump in your legs or arms.  These could be signs of a blood clot. </dd>
<dt>•</dt>
<dd>Brown or red urine, fast heart rate, <span class="product-label-link" type="condition" conceptid="4021666" conceptname="Yellow skin">yellow skin</span> or eyes.  These could be signs of a liver problem or a blood problem.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> or trouble breathing, or blue lips or extremities.  These could be signs of a serious heart or lung problem.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> over 100°F.  This could be a sign of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </dd>
</dl>
<p>These are not all of the possible side effects with GAMMAGARD LIQUID.  You can ask your healthcare provider for physician’s information leaflet. Tell your healthcare provider about any side effect that bothers you or that does not go away.</p>
<p>Whenever giving yourself treatments at home, you should have another responsible person present to help treat side effects or get help if you have a serious adverse reaction occur.  Ask your healthcare provider whether you should have rescue medications, such as antihistamines or epinephrine. </p>
<p><span class="Bold">How do I store GAMMAGARD LIQUID?</span></p>
<p>Store vials in their original boxes to protect from light.  Do not freeze GAMMAGARD LIQUID.<span class="Bold"></span>You can store GAMMAGARD LIQUID in the refrigerator or at room temperature.  The maximum storage time for GAMMAGARD LIQUID depends on the storage temperature you choose.</p>
<p><span class="Bold">In the Refrigerator: </span>at 2° to 8°C (36° to 46°F) for up to 36 months.</p>
<p><span class="Bold">Room Temperature: </span>up to 25°C (77°F) for up to 24 months.</p>
<p>The refrigerator and room temperature expiration dates are printed on the vial labels and the box.  Always check the expiration date.  You should not use the product after the expiration date.</p>
<p>Note: If you remove GAMMAGARD LIQUID from the refrigerator and store it at room temperature, do not refrigerate again.</p>
<p><span class="Bold">Resources at Baxter Available to the Patients:</span></p>
<p>For more information on patient resources, education, or insurance assistance please visit <a href="http://www.immunedisease.com/">www.immunedisease.com</a>.</p>
<p><span class="Bold">Detailed Instructions for Subcutaneous Administration for Patients with PI ONLY</span></p>
<p>Do not begin subcutaneous treatment with GAMMAGARD LIQUID until you have received instructions as detailed above and are comfortable that you can perform all the steps on your own.  </p>
<table width="100%">
<col width="58%">
<col width="42%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule">
<p class="First"><span class="Bold">1.  If refrigerated, remove GAMMAGARD LIQUID from refrigerator</span>- remove the product box from the refrigerator and take the vial out of the box.</p>
<p>Allow vials to reach room temperature.This may take up to 60 minutes.</p>
<p><span class="Bold">Do not heat up the product or shake the product. </span></p>
<p>If stored at room temperature, take the vial out of the box. </p>
<p>Check:</p>
<dl>
<dt>•</dt>
<dd>Expiration date.  Do not use beyond expiration date.  </dd>
<dt>•</dt>
<dd>Vial to see if it is clear and colorless to light yellow. If it is cloudy or has particles, do not use. </dd>
<dt>•</dt>
<dd>Protective cap is on the vial. Do not use the product if it does not have the cap. </dd>
</dl>
<p>Repeat this step with as many boxes of GAMMAGARD LIQUID as necessary.</p>
</td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">2.  Gather all supplies</span> – Collect all the items you will need for the infusion: vial(s) of GAMMAGARD LIQUID, infusion supplies (needle sets, transfer needles, alcohol swabs, syringes, gauze, and tape), sharps container, infusion pump, and treatment logbook.</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">3.  Prepare a clean work area-</span> Clean a work area with an antibacterial cleaner and place all gathered items on the clean surface. Find a quiet work area with as few distractions as possible.</p></td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2376"></a><img alt="Clean a work area with an antibacterial cleaner and place all gathered items on the clean surface. Find a quiet work area with as few distractions as possible." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-08.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">4.  Wash hands- </span>Wash your hands thoroughly. Put on clean gloves if your health care provider has instructed you to wear them.</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First"><span class="Bold">5.  GAMMAGARD LIQUID preparation-</span> If GAMMAGARD LIQUID is received in a bag or syringe, skip to step 7. </p>
<p>Remove the cap from the vial. Wipe the vial stopper with an alcohol swab and allow to air dry (at least 30 seconds).</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2390"></a><img alt="If GAMMAGARD LIQUID is received in a bag or syringe, skip to step 7.  Remove the cap from the vial. Wipe the vial stopper with an alcohol swab and allow to air dry (at least 30 seconds)." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-09.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First"><span class="Bold">6.  Fill syringe from GAMMAGARD LIQUID vial(s)</span> – Remove sterile syringe from package and attach to a sterile needle. Pull back on plunger of the syringe to fill it with air, which should equal the amount of liquid you will be taking from the vial. Insert needle into the center of the vial stopper. Inject air into the vial and withdraw GAMMAGARD LIQUID into the syringe. (Example: If withdrawing 50 mL of GAMMAGARD LIQUID, inject 50 mL of air into the vial). </p>
<p>If multiple vials are required to achieve the desired dose, repeat this step. </p>
<p>If using a vented spike, it is not necessary to inject air into the vial with the syringe. Attach a sterile syringe to the spike, insert the spike into the center of the stopper, and pull back on the plunger to withdraw the desired volume.</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2401"></a><img alt="Remove sterile syringe from package and attach to a sterile needle. Pull back on plunger of the syringe to fill it with air, which should equal the amount of liquid you will be taking from the vial. Insert needle into the center of the vial stopper. Inject air into the vial and withdraw GAMMAGARD LIQUID into the syringe." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-10.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First"><span class="Bold">7.  Prepare the infusion pump and tubing </span>– If using a syringe driver pump, attach the syringe filled with GAMMAGARD LIQUID to the needle set. On a hard surface, gently push down on the plunger to fill (prime) the pump tubing up to the needle hub. This will ensure that no air is left in the tubing and needle (see picture).</p>
<p>If using a portable pump with GAMMAGARD LIQUID in a bag, follow manufacturer’s instructions for preparing the pump and administration tubing, if needed.</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2413"></a><img alt="If using a syringe driver pump, attach the syringe filled with GAMMAGARD LIQUID to the needle set. On a hard surface, gently push down on the plunger to fill (prime) the pump tubing up to the needle hub. This will ensure that no air is left in the tubing and needle ." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-11.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First"><span class="Bold">8.  Select the infusion sites</span> - Select the number of infusion sites based on the volume of the total dose. It is recommended that you not inject more than 20 mL for children and 30 mL for adults into each infusion site. </p>
<p>See figure for potential locations of infusion sites (e.g., upper arms, abdomen, thighs, and lower back).  Make sure sites are at least 2 inches apart.  Avoid bony areas, visible blood vessels, <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span> and areas of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (irritation) or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2423"></a><img alt="Select the number of infusion sites based on the volume of the total dose. It is recommended that you not inject more than 20 mL for children and 30 mL for adults into each infusion site." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-12.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">9.  Clean the infusion site(s)-</span> Clean the infusion site(s) with an alcohol swab. Allow to dry (at least 30 seconds).</p></td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2430"></a><img alt="Clean the infusion site(s) with an alcohol swab. Allow to dry (at least 30 seconds)." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-13.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">10. Insert the needle</span> – Remove the needle cover.  Firmly grasp skin and pinch at least one inch of skin between two fingers.   Insert needle with a rapid motion straight into the skin at a 90 degree angle.  Tape the needle in place. Repeat this step for each infusion site.</p></td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2437"></a><img alt="Remove the needle cover.  Firmly grasp skin and pinch at least one inch of skin between two fingers.   Insert needle with a rapid motion straight into the skin at a 90 degree angle.  Tape the needle in place. Repeat this step for each infusion site." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-14.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">11. Check for proper needle placement</span> – Before starting the infusion, check each needle for correct placement by gently pulling back on the attached syringe plunger and looking for any blood in the needle tubing.  If you see any blood, remove and throw away the needle into the sharps container. Repeat filling (priming) and needle insertion steps in a different infusion site with a new needle.</p></td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2444"></a><img alt="Before starting the infusion, check each needle for correct placement by gently pulling back on the attached syringe plunger and looking for any blood in the needle tubing.  If you see any blood, remove and throw away the needle into the sharps container. Repeat filling (priming) and needle insertion steps in a different infusion site with a new needle." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-15.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First"><span class="Bold">12. Secure the needle to the skin and start infusion</span> - Secure the needle(s) in place by putting a sterile clear bandage over the needle.</p>
<p>Follow the manufacturer’s instructions to turn pump on. Check infusion sites occasionally throughout the infusion.</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2454"></a><img alt="Secure the needle(s) in place by putting a sterile clear bandage over the needle." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-16.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First"><span class="Bold">13. Remove needle set – </span>After the infusion is complete, remove the needle set by pulling it straight out. Gently press a small piece of gauze over the needle site and cover with a protective dressing.  </p>
<p>Throw away any unused product in the vial and the disposable supplies into the sharps container. Dispose of the sharps container using instructions provided with the container, or contact your healthcare provider.</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<a name="id2464"></a><img alt="After the infusion is complete, remove the needle set by pulling it straight out. Gently press a small piece of gauze over the needle site and cover with a protective dressing" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-17.jpg"><p class="MultiMediaCaptionNotCentered"></p>
<p class="First"></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">14. Record the infusion</span> - Remove the peel-off label from GAMMAGARD LIQUID vial, which has the product lot number and expiration date, and place the label in your treatment diary/log book. Write down the date, time, dose, and any reactions after each infusion.</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
</tbody>
</table>
<p><br>Baxter and Gammagard Liquid are trademarks of Baxter International Inc. </p>
<p>Baxter Healthcare Corporation </p>
<p>Westlake Village, CA 91362 USA </p>
<p>U.S. License No. 140</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f41fa58d-2e7a-411f-ae76-2da3dd6e9f6d"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure">
<a name="id2482"></a><img alt=" GAMMAGARD LIQUID 1g Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-18.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 1g Vial Label </p>
</div>
<p class="First">GAMMAGARD LIQUID 1g Vial Label </p>
<p>NDC 0944-2700-08</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion </span></p>
<p><span class="Bold">(Human) 10%</span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">1g 10mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Use.</span></p>
<p>Not made with natural rubber latex.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation,</span></p>
<p>Westlake Village, </p>
<p>CA 91362 USA, U.S. License No. 140</p>
<p>Lot No.:</p>
<p>Refrigeration Exp Date:</p>
<p>Room Temp:</p>
<p>Exp Date:</p>
<div class="Figure">
<a name="id2512"></a><img alt=" GAMMAGARD LIQUID 1g Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-19.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 1g Unit Carton </p>
</div>
<p>GAMMAGARD LIQUID 1g Unit Carton </p>
<p>NDC 0944-2700-02</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion </span></p>
<p><span class="Bold">(Human) 10%</span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">1g 10mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration</span></p>
<div class="Figure">
<a name="id2531"></a><img alt="GAMMAGARD LIQUID 2.5g Vial Labe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-20.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 2.5g Vial Label </p>
</div>
<p>GAMMAGARD LIQUID 2.5g Vial Label </p>
<p>NDC 0944-2700-09</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion </span></p>
<p><span class="Bold">(Human) 10%</span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">2.5g 25mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Use.</span></p>
<p>Not made with natural rubber latex.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation,</span></p>
<p>Westlake Village, </p>
<p>CA 91362 USA, U.S. License No. 140</p>
<p>Lot No.:</p>
<p>Refrigeration Exp Date:</p>
<p>Room Temp:</p>
<p>Exp Date:</p>
<div class="Figure">
<a name="id2562"></a><img alt=" GAMMAGARD LIQUID 2.5g Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-21.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 2.5g Unit Carton </p>
</div>
<p>GAMMAGARD LIQUID 2.5g Unit Carton </p>
<p>NDC 0944-2700-03</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion </span></p>
<p><span class="Bold">(Human) 10%</span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">2.5g 25mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration</span></p>
<div class="Figure">
<a name="id2583"></a><img alt="GAMMAGARD LIQUID 5g Vial Labe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-22.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 5g Vial Label </p>
</div>
<p>GAMMAGARD LIQUID 5g Vial Label </p>
<p>NDC 0944-2700-10</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion (Human) 10% </span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">5g 50mL</span></p>
<p><span class="Bold">Solution for Infusion </span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration.</span></p>
<p>Not made with natural rubber latex.<br><span class="Bold">Refrigeration:</span> 2˚ -8˚C (36˚F -46˚F).  Do Not Freeze.</p>
<p><span class="Bold">Room temperature: </span>up to 25˚C (77˚ F).</p>
<p><span class="Bold">Rx Only </span></p>
<p><span class="Bold">Baxter Healthcare Corporation, </span></p>
<p>Westlake Village, CA 91362 USA</p>
<p>U.S. License No. 140</p>
<p>Lot No.:</p>
<p>Refrigeration Exp Date:</p>
<p>Room Temp:</p>
<p>Exp Date:</p>
<div class="Figure">
<a name="id2615"></a><img alt="GAMMAGARD LIQUID 5g Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-23.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 5g Unit Carton </p>
</div>
<p>GAMMAGARD LIQUID 5g Unit Carton </p>
<p>NDC 0944-2700-04</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion </span></p>
<p><span class="Bold">(Human) 10%</span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">5g 50mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration</span></p>
<div class="Figure">
<a name="id2636"></a><img alt="GAMMAGARD LIQUID 10g Vial Labe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-24.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 10g Vial Label </p>
</div>
<p>GAMMAGARD LIQUID 10g Vial Label </p>
<p>NDC 0944-2700-11</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion (Human) 10% </span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">10g 100mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration.</span></p>
<p>Not made with natural rubber latex. </p>
<p><span class="Bold">Refrigeration: </span>2˚ -8˚C (36˚F -46˚F).</p>
<p><span class="Bold">Room temperature: </span>up to 25˚C (77˚ F).</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation,</span></p>
<p>Westlake Village, CA 91362 USA</p>
<p>U.S. License No. 140</p>
<p>Lot No.:</p>
<p>Refrigeration Exp Date:</p>
<p>Room Temp:</p>
<p>Exp Date:</p>
<div class="Figure">
<a name="id2667"></a><img alt=" GAMMAGARD LIQUID 10g Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-25.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 10g Unit Carton </p>
</div>
<p>GAMMAGARD LIQUID 10g Unit Carton </p>
<p>NDC 0944-2700-05</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion</span></p>
<p><span class="Bold">(Human) 10%</span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">10g 100mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration</span></p>
<div class="Figure">
<a name="id2689"></a><img alt=" GAMMAGARD LIQUID 20g Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-26.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 20g Vial Label </p>
</div>
<p>GAMMAGARD LIQUID 20g Vial Label </p>
<p>NDC 0944-2700-12</p>
<p><span class="Bold">Immune Globulin Infusion (Human) 10% </span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">20g 200mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration.</span></p>
<p>Not made with natural rubber latex.</p>
<p><span class="Bold">Refrigeration: </span>2˚ -8˚C (36˚F -46˚F).  Do Not Freeze.</p>
<p><span class="Bold">Room temperature: </span>up to 25˚C (77˚ F). </p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation, </span></p>
<p>Westlake Village, CA 91362 USA</p>
<p>U.S. License No. 140</p>
<p>Lot No.:</p>
<p>Refrigeration Exp Date:</p>
<p>Room Temp:</p>
<p>Exp Date:</p>
<div class="Figure">
<a name="id2722"></a><img alt="GAMMAGARD LIQUID 20g Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-27.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 20g Unit Carton </p>
</div>
<p>GAMMAGARD LIQUID 20g Unit Carton </p>
<p>NDC 0944-2700-06</p>
<p><span class="Bold">Immune Globulin Infusion</span></p>
<p><span class="Bold">(Human) 10%</span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">20g 200mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration</span></p>
<div class="Figure">
<a name="id2743"></a><img alt=" GAMMAGARD LIQUID 30g Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-28.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 30g Vial Label </p>
</div>
<p>GAMMAGARD LIQUID 30g Vial Label </p>
<p>NDC 0944-2700-13</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion (Human) 10% </span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">30g 300mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration.</span></p>
<p>Not made with natural rubber latex.</p>
<p><span class="Bold">Refrigeration: </span>2˚ -8˚C (36˚F -46˚F).  Do Not Freeze.</p>
<p><span class="Bold">Room temperature: </span>up to 25˚C (77˚ F).</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation, </span></p>
<p>Westlake Village, CA 91362 USA</p>
<p>U.S. License No. 140</p>
<p>Lot No.:</p>
<p>Refrigeration Exp Date:</p>
<p>Room Temp:</p>
<p>Exp Date:</p>
<div class="Figure">
<a name="id2775"></a><img alt="GAMMAGARD LIQUID 30g Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130&amp;name=image-29.jpg"><p class="MultiMediaCaption">GAMMAGARD LIQUID 30g Unit Carton </p>
</div>
<p>GAMMAGARD LIQUID 30g Unit Carton </p>
<p>NDC 0944-2700-07</p>
<p>Single-dose container</p>
<p><span class="Bold">Immune Globulin Infusion</span></p>
<p><span class="Bold">(Human) 10%</span></p>
<p><span class="Bold">GAMMAGARD LIQUID</span></p>
<p><span class="Bold">30g 300mL</span></p>
<p><span class="Bold">Solution for Infusion</span></p>
<p><span class="Bold">For Intravenous or Subcutaneous Administration</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GAMMAGARD 		
					</strong><br><span class="contentTableReg">human <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin g</span> injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-2700</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></strong> (HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span>) </td>
<td class="formItem">HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-2700-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-2700-08</td>
<td class="formItem">10 mL in 1 BOTTLE, GLASS; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0944-2700-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0944-2700-09</td>
<td class="formItem">25 mL in 1 BOTTLE, GLASS; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0944-2700-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0944-2700-10</td>
<td class="formItem">50 mL in 1 BOTTLE, GLASS; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0944-2700-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0944-2700-11</td>
<td class="formItem">100 mL in 1 BOTTLE, GLASS; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:0944-2700-06</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:0944-2700-12</td>
<td class="formItem">200 mL in 1 BOTTLE, GLASS; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:0944-2700-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:0944-2700-13</td>
<td class="formItem">300 mL in 1 BOTTLE, GLASS; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125105</td>
<td class="formItem">04/27/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(039121363)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter SA</td>
<td class="formItem"></td>
<td class="formItem">370191025</td>
<td class="formItem">MANUFACTURE(0944-2700)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>97974bae-2df8-484f-a964-0fb7ff6a57c9</div>
<div>Set id: 9d42adca-0dd7-4df7-864d-5a7feee52130</div>
<div>Version: 8</div>
<div>Effective Time: 20130905</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
